prepared by

David Wilson, Melanie Middleton, Ann McDonald, Libby Topp and Joanne Micallef.

The Kirby Institute

in collaboration with

National BBV and STI Surveillance Subcommittee
of Communicable Diseases Network Australia
Contents

Preface 5
Executive Summary 7
Background 13
Hepatitis B 15
Reduce hepatitis B infections 15
Reduce the proportion of people with chronic hepatitis B who have not been diagnosed 17
Improve the health and wellbeing of people with chronic hepatitis B 20
Hepatitis C 23
Reduce the incidence of hepatitis C 23
Increase access to new injecting equipment through needle and syringe programs 25
Reduce the burden of disease attributed to chronic hepatitis C 26
Increase access to clinical care for people with chronic hepatitis C 27
Reduce hepatitis C-related stigma and discrimination in healthcare settings 29
HIV 31
Reduce the incidence of HIV 31
Reduce the risk behaviours associated with the transmission of HIV 34
Increase the proportion of people living with HIV on treatments with undetectable viral load 36
Decrease the number of people with undiagnosed HIV infection 38
Improve the quality of life of people living with HIV 40
Sexually Transmissible Infections 43
Reduce the incidence of gonorrhoea 43
Reduce the incidence of infectious syphilis 46
Reduce the incidence of chlamydia 48
Increase testing for chlamydia among priority populations 51
Increase young people’s knowledge of STIs 53
Incorporate STI-related prevention and treatment into broader health reforms 54
Aboriginal and Torres Strait Islander Blood-borne Viruses and STIs 57
Reduce hepatitis B infections 57
Work towards eliminating infectious syphilis in Aboriginal and Torres Strait Islander people 59
Increase the level of testing and treatment of sexually active 15 – 30 year olds 64
Improve Aboriginal and Torres Strait Islander people’s knowledge of STIs and BBVs 65
Increase the number of Aboriginal and Torres Strait Islander peoples receiving treatment for HIV, hepatitis C and hepatitis B 65
Implement a national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers 66
References 67
Glossary 71
Acknowledgements 73
Preface


We are pleased to introduce this first report providing an annual account of progress against the goals and objectives of Australia’s national BBV and STI strategies.

In April 2010, Australia’s Federal, State and Territory Health Ministers endorsed new national strategies for HIV, STIs, Hepatitis B and Hepatitis C together with a new National Aboriginal and Torres Strait Islander BBV and STI Strategy. The five national strategies cover the period 2010-2013.

For the first time, each of these national strategies includes specific measurable indicators against each of the strategy objectives. In 2011, the Communicable Diseases Network Australia (CDNA) developed and released the National BBV and STI Surveillance and Monitoring Plan that provides the data specifications for each of these indicators.

In this first annual report against the indicators, we see the results of this work. For each of the highest priority objectives of the national strategies, this report presents data describing the nature and magnitude of the challenge, and the level of progress being made in response.

We thank Dr Christine Selvey, Queensland’s representative to CDNA, for leading the development of the National BBV and STI Surveillance and Monitoring Plan and overseeing the publication of this report. We also acknowledge Associate Professor David Wilson from the Kirby Institute, and his research and surveillance colleagues, for their work in assembling this report. And we thank the many individuals who have provided leadership and input into the development of the plan and this report over the past year.

This report provides important intelligence and insights into the challenges of BBV and STI response and control in Australia. It provides measurement of the effectiveness of our national response and highlights areas requiring additional attention.

In 2012, the Australian Government’s Ministerial Advisory Committee on BBVs and STIs (MACBBVS) and the inter-governmental BBV and STIs Sub-Committee (BBVSS) will continue their efforts in providing advice and leadership in responding to these challenges.

Professor Michael Kidd AM
Chair
MACBBVS

Dr Kerry Chant
Chair
BBVSS
Executive Summary

In April 2010, a suite of National Strategies for the prevention and management of Human Immunodeficiency Virus (HIV), sexually transmissible infections (STIs), hepatitis B and hepatitis C, including in Aboriginal and Torres Strait Islander communities were endorsed by the Australian Health Ministers’ Conference.

The aims of these National Strategies are to:

- Reduce the transmission of HIV, STIs, hepatitis B and hepatitis C;
- Reduce the morbidity, mortality and personal and social impacts they cause.

This report presents available data that align with indicators associated with monitoring progress against these goals. Objectives and summaries of progress are summarised in the tables below for each of the National Strategies.

**Hepatitis B Strategy, 2010 – 2013**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reduce hepatitis B infections</strong></td>
<td>Although the hepatitis B vaccination program is successfully reaching coverage of approximately 95% among infants, there are still 1530 - 2600 new incident cases of hepatitis B occurring annually. Other evidence suggests this is primarily occurring in priority populations such as people who inject drugs, men who have sex with men, and Indigenous Australians. The weak evidence available suggests that local transmission of hepatitis B is slowly declining.</td>
</tr>
<tr>
<td><strong>Reduce the proportion of people with chronic hepatitis B who have not been diagnosed</strong></td>
<td>Available evidence for estimating the extent of undiagnosed chronic hepatitis B infection is relatively weak, but suggests that there has not been a substantial change in the level of undiagnosed infections. Estimates suggest approximately 40% of people chronically infected with hepatitis B are undiagnosed.</td>
</tr>
<tr>
<td><strong>Improve the health and wellbeing of people with chronic hepatitis B</strong></td>
<td>No rigorous data are currently available for monitoring the health and wellbeing of people with chronic hepatitis B. New data collection options need to be considered for determining the extent of regular monitoring for hepatocellular carcinoma (HCC) and retrospective reviews should be carried out of a random sample of cases of HCC to estimate the attributable fraction of disease associated with hepatitis B.</td>
</tr>
</tbody>
</table>
## Hepatitis C Strategy, 2010 – 2013

<table>
<thead>
<tr>
<th>Objective</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reduce the incidence of hepatitis C</strong></td>
<td>Data indicate that hepatitis C incidence ranges between 5 and 22 per 100 person-years among people who inject drugs (PWID) but there is no evidence of a decreasing or increasing time trend.</td>
</tr>
<tr>
<td><strong>Increase access to new injecting equipment through needle and syringe programs</strong></td>
<td>Access to new injecting equipment through needle and syringe programs appears to be relatively stable since 2001, with around one in six PWID who participate in the Annual Needle Syringe Program Survey (ANSPS) continuing to report recent receptive sharing of injecting equipment.</td>
</tr>
<tr>
<td><strong>Reduce the burden of disease attributed to chronic hepatitis C</strong></td>
<td>Limited rigorous data are systematically collated to allow comprehensive monitoring of hepatitis C-related burden of disease. Modelling estimates suggest that hepatitis C-related burden of disease, including advanced liver disease, is high (with approximately 300 000 people in Australia infected of whom ~6 000 have hepatitis C-related cirrhosis, leading to about 250 liver failure cases and 120 cases of hepatocellular carcinoma (HCC) each year).</td>
</tr>
<tr>
<td><strong>Increase access to clinical care for people with chronic hepatitis C</strong></td>
<td>Data suggest that access to antiviral therapy for chronic hepatitis C has almost doubled since 2004 but recently stabilised. However, other evidence shows the proportion of chronically infected people receiving hepatitis C treatment is low at only 10 - 12%.</td>
</tr>
<tr>
<td><strong>Reduce hepatitis C-related stigma and discrimination in healthcare settings</strong></td>
<td>No data are available on hepatitis C-related stigma and discrimination.</td>
</tr>
</tbody>
</table>
### HIV Strategy, 2010 - 2013

<table>
<thead>
<tr>
<th>Objective</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce the incidence of HIV</td>
<td>There is reasonably strong evidence that HIV incidence across Australia has recently stabilised at around 4.6 per 100 000 population after increasing trends. HIV incidence may be slightly decreasing in a few jurisdictions but continues to increase in Queensland and Western Australia.</td>
</tr>
<tr>
<td>Reduce the risk behaviours associated with the transmission of HIV</td>
<td>Sexual behaviour risk, measured through the Gay Community Periodic Surveys (GCPS) by reports of unprotected anal intercourse with casual partners, indicated a small increase over the past 10 years from 20% to 22%. The extent of sharing of used syringes by people who inject drugs seen through needle and syringe programs is about 13 - 14% and has not changed over the past 10 years.</td>
</tr>
<tr>
<td>Increase the proportion of people living with HIV on treatments with undetectable viral load</td>
<td>Although there has been a steady increase in the number of people dispensed antiretroviral treatment for HIV infection over the past ten years, the estimated proportion (52%) dispensed antiretroviral treatment does not appear to have changed from the relatively high baseline levels. On the other hand, the extent of viral suppression among people on antiretroviral therapy (ART) has substantially increased over this period to ~80%. Taken together, these factors mean that the proportion of people living with HIV on treatments with undetectable viral load has substantially increased.</td>
</tr>
<tr>
<td>Decrease the number of people with undiagnosed HIV infection</td>
<td>There is inconclusive evidence about trends in undiagnosed HIV infections with some indications that the number and proportion of people with undiagnosed HIV infection may be increasing.</td>
</tr>
<tr>
<td>Improve the quality of life of people living with HIV</td>
<td>Perceived quality of life of people living with HIV appears to have slightly increased, with close to three-quarters reporting their health as ‘good’ or ‘excellent’.</td>
</tr>
<tr>
<td>Objective</td>
<td>Progress</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Reduce the incidence of gonorrhoea</td>
<td>Gonorrhoea is a two pronged epidemic. The available evidence for gonorrhoea incidence suggests that incidence may be increasing for men who have sex with men, with the notification rate in men increasing 26% to over 60 per 100,000 population. The same evidence suggests that incidence in Aboriginal and Torres Strait Islander people that had been declining increased in 2010 to 804 per 100,000 population.</td>
</tr>
<tr>
<td>Reduce the incidence of infectious syphilis</td>
<td>The available evidence suggests that incidence of syphilis in men who have sex with men is currently declining to 4.9 per 100,000 population after reaching 6.7 in a large resurgence in the years 2000-2007. While there have been recent decreases in remote Aboriginal communities, there are continuing outbreaks.</td>
</tr>
<tr>
<td>Reduce the incidence of chlamydia</td>
<td>The available evidence for chlamydia incidence is weak, but suggestive that incidence is likely to be slightly increasing. Positivity levels increased by more than 5% in Aboriginal and Torres Strait Islander people and young heterosexual women, and lesser amounts in other priority groups. The proportion of chlamydia tests that were positive increased for the first time in 2010, with a 1% increase to 15.1% in people aged 15-24 years. It is too early to determine whether this is part of a continuing trend.</td>
</tr>
<tr>
<td>Increase testing for chlamydia among priority populations</td>
<td>There has been a substantial increase in the rate of chlamydia testing among young people aged 15–24 years in Australia over the past 10 years with up to 10% of young people tested in 2010. The rate of testing in men who have sex with men is approximately 65% and has not increased over this same timeframe.</td>
</tr>
<tr>
<td>Increase young people’s knowledge of STI</td>
<td>STI knowledge among young people has improved over time, but the level of knowledge is variable and generally low.</td>
</tr>
<tr>
<td>Incorporate STI-related prevention and treatment into broader health reforms</td>
<td>There is evidence that STI treatment and prevention has become more integrated into broader healthcare to some extent. The proportion of chlamydia tests carried out for every GP consultation has increased over the past 10 years from less than 1 to 3.5 tests per 100 GP visits. This increase has been more marked in women than in men.</td>
</tr>
</tbody>
</table>
### Objective Progress

<table>
<thead>
<tr>
<th>Objective</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reduce hepatitis B infections</strong></td>
<td>Although small numbers of newly acquired Hepatitis B infection occur each year, rates are substantially higher among Aboriginal and Torres Strait Islander communities than among non-Indigenous Australians. Vaccination coverage is excellent among infants at over 90% for children at 24 months of age.</td>
</tr>
<tr>
<td><strong>Work towards eliminating infectious syphilis in Aboriginal and Torres Strait Islander people</strong></td>
<td>Although there has been an observed decrease in the rate of infectious syphilis notifications in the Aboriginal and Torres Strait Islander population over the past five years from 234 per 100,000 in 2006 to 130 in 2010, this rate is still five times greater than in the non-Indigenous population.</td>
</tr>
<tr>
<td><strong>Decrease the proportion of HIV and hepatitis C infection caused by injecting drug use</strong></td>
<td>A much higher proportion of Aboriginal and Torres Strait Islander people (19%) with HIV report injecting drug use as primary mode of transmission compared to non Indigenous people (3%). Relevant data are not available for hepatitis C.</td>
</tr>
<tr>
<td><strong>Increase the level of testing and treatment of sexually active 15-30 year olds</strong></td>
<td>No data are available on STI testing and treatment levels among young sexually active Aboriginal and Torres Strait Islander people. Project specific data will become available over the life of the strategies to effectively monitor this goal.</td>
</tr>
<tr>
<td><strong>Improve Aboriginal and Torres Strait Islander people’s knowledge of STIs and BBVs</strong></td>
<td>No data are available on knowledge of STIs and blood borne viruses (BBVs) among Aboriginal and Torres Strait Islander people. Project specific data will become available over the life of the strategies to effectively monitor this goal.</td>
</tr>
<tr>
<td><strong>Increase the number of Aboriginal and Torres Strait Islander peoples receiving treatment for HIV, hepatitis C and hepatitis B</strong></td>
<td>Data for treatment coverage of HIV, chronic hepatitis C and chronic hepatitis B among Aboriginal and Torres Strait Islander people are currently unavailable.</td>
</tr>
<tr>
<td><strong>Implement a national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers</strong></td>
<td>A national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers is not yet implemented.</td>
</tr>
</tbody>
</table>
Background

On 22 April 2010, the Australian Health Ministers' Conference endorsed a suite of National Strategies for the prevention and management of HIV, STIs, hepatitis B and hepatitis C, including in Aboriginal and Torres Strait Islander communities. The National Strategies are:

- Sixth National HIV Strategy 2010 – 2013
- Second National Sexually Transmissible Infections Strategy 2010 – 2013
- Third National Hepatitis C Strategy 2010 – 2013
- National Hepatitis B Strategy 2010 – 2013

The aims of these National Strategies are to reduce the transmission of HIV, STIs, hepatitis B and hepatitis C, and to reduce the morbidity, mortality and personal and social impacts they cause. Each of the National Strategies outlines a set of indicators for monitoring progress towards reaching these goals. The development of a Surveillance and Monitoring Plan for reporting against these indicators was identified in the National Strategies as a key step in the implementation process.

The development of the National BBV and STI Surveillance and Monitoring Plan was led by a steering committee under the auspices of the Communicable Diseases Network Australia (CDNA), and has become a supporting document to the National Strategies for BBV and STI. The formal process consisted of these key actions:

- Consultation with key national policy and surveillance organisations from all jurisdictions;
- Establishment of the National BBV and STI Surveillance and Monitoring Plan Steering Committee, which reported to CDNA. The Steering Committee included experts from all jurisdictions and from a range of backgrounds including researchers, policy officers, surveillance officers, and other stakeholders (see Acknowledgements).
- Establishment of five area-specific working groups (one for each of the National Strategies) that made recommendations of how to measure the indicators for the five National Strategies, and identified potential barriers and resource burdens for measuring each indicator. Recommendations were made to vary some of the indicators in the National Strategies to make them more relevant and feasible.
- The working groups, Steering Committee and other stakeholders met at a national workshop in April 2011. The purpose of the workshop was to prioritise data collection for each of the indicators, review the resource burden of the proposed measures, and to discuss implementation, reporting and governance of the National BBV and STI Surveillance and Monitoring Plan.
- The Plan was reviewed and endorsed by the Steering Committee Executive, working group chairs, CDNA, the Australian Health Protection Committee (AHPC), the Blood Borne Virus and Sexually Transmissible Infections Sub-Committee (BBVSS) of the Australian Population Health Development Principal Committee (APHDPC), and APHDPC.

The Kirby Institute, University of New South Wales, has responsibility for producing an annual report for the National BBV and STI Surveillance and Monitoring Plan over the life of the National Strategies, until 2013. This first report was produced by a Surveillance and Monitoring Report Internal Working Group of the Kirby Institute (see Acknowledgements). The National BBV and STI Surveillance and Monitoring Plan Steering Committee and the National Blood Borne Virus and Sexually Transmissible Infection Surveillance Sub-Committee of CDNA (see Acknowledgements) also oversee this report and provide advice to CDNA on the ongoing priorities for implementation of the National BBV and STI Surveillance and Monitoring Plan based on indicator priorities and resource burden of data collection.
The indicators presented in this report are drawn directly from the five National BBV and STI Strategies and provide information about how Australia is progressing in controlling BBVs and STIs in terms of risk behaviours and incidence of infection and disease morbidity as well as quality of life, including the personal and social impacts of these infections. However, the indicators do not represent a comprehensive set of data that measures all aspects of the BBV and STI ‘landscape’ in Australia. What is not well-represented in the Surveillance and Monitoring Plan is the myriad of social factors and complex human behaviours that underlie the transmission of BBVs and STIs, or the clinical environments in which BBV and STI testing and treatment takes place. An understanding of these factors is crucial to the national response to BBVs and STIs.

The data presented in this report represent the best data identified and currently available which align to indicators for monitoring progress against the objectives of the National Strategies. The data presented in this report have been collected by a range of organisations and from different populations. Many of the data sources are imperfect but provide a means to draw qualitative and some quantitative conclusions. Some data components identified in the National BBV and STI Surveillance and Monitoring Plan rely on the establishment of new surveillance systems, new models or data linkage between existing data sets. Some of the data sources identified in the Plan do not have recurrent funding and some new priority data collections will only proceed if new resources are made available. In some cases, multiple organisations may have the capacity to develop and implement the surveillance system, should resources become available.

Australia has been relatively successful in containing epidemics of blood-borne viral and sexually transmissible infections compared to many other high-income countries. However, continued vigilance and action is required to reduce escalating rates of some infections and to maintain decreasing trends for others. The successful Australian ‘partnership model’ which was established in response to the HIV/AIDS epidemic and now covers policy and program activities associated with HIV, viral hepatitis and sexually transmissible infections must continue to work together. This model brings together government, community, clinicians, researchers and health sector workforce organisations to ensure that all aspects of the response are working together and that all perspectives, across multiple disciplines, are able to inform each other.

Leadership of the response to blood-borne viral and sexually transmissible infections in Australia is provided by the Australian government which works through the Australian Health Ministers Council (AHMC) and its sub-committees to facilitate national policy formulation and coordination. BBVSS includes representatives of the ‘partnership’ and provides expert advice to health ministers through APHDPC and AHMAC. The Australian government also seeks advice through the Ministerial Advisory Committee for Blood Borne Viruses and Sexually Transmissible Infections (MACBBVS). Based on evidence presented in this report, these groups will work in the context of funding arrangements for the health system to reshape existing policies and programs and surveillance systems or to extend them where possible in order to have maximal success of achieving the objectives of the National Strategies.

The National BBV & STI Surveillance Subcommittee of CDNA will undertake regular review of the data sources for the indicators highlighted in these reports. The Subcommittee will make recommendations to CDNA if there are changes or alterations to data sources and following changes to the National Strategies.
Hepatitis B

As of the end of 2010, it is estimated that ~170 000 (139 000-201 000) people in Australia were living with hepatitis B infection (HBsAg positive); that is, an overall prevalence of ~1% in the adult population. However, certain populations have much higher hepatitis B prevalence, notably, people who inject drugs (2.5-7.5%), Indigenous Australians (3.1-8.9%), people born in Southeast Asia (3.9-23.7%), and HIV-positive men who have sex with men (1.9-7.2%). An estimated 335 (259-544) deaths were attributable to chronic hepatitis B in Australia in 2010.

The National hepatitis B Strategy 2010 – 2013 identified three specific objectives, with associated indicators:

1. **Reduce hepatitis B infections**
   - Incidence of hepatitis B
   - Coverage of hepatitis B vaccination at 12 and 24 months

2. **Reduce the proportion of people with chronic hepatitis B who have not been diagnosed**
   - Estimated proportion of people with chronic hepatitis B who have not been diagnosed
   - Notifications of newly acquired and unspecified hepatitis
   - Proportion of people who die from hepatocellular carcinoma within 12 months of hepatitis B diagnosis

3. **To improve the health and wellbeing of people with chronic hepatitis B**
   - Proportion of people with chronic hepatitis B who are screened 6 monthly for hepatocellular carcinoma
   - Proportion of hepatocellular carcinoma attributable to hepatitis B
   - Proportion of people with chronic hepatitis B dispensed drugs for hepatitis B infection through the Highly Specialised Drugs Program

**Reduce hepatitis B infections**

The need to continue to prevent new infections is a major issue relating to hepatitis B in Australia. Given that a large proportion of incident hepatitis B infections are asymptomatic, the ideal measure would be serial serological testing of all people to document seroconversion to anti-HBc positivity on an annual basis to document all infections occurring in the population [1-3]. Other approaches used internationally include active (as opposed to passive) surveillance, particularly in priority populations at higher risk of infection [4]; seroprevalence surveys of convenience samples with mathematical modelling to estimate incidence of infection; and large scale population serosurveys, such as the ANSPS for injecting drug users in which anti-HBc positivity could be measured, again with modelling to estimate incidence of infection within this population. These are all limited by costs, and also difficulties in distinguishing infections acquired in adulthood from those acquired earlier in life, particularly among people from high prevalence countries.

With available resources, Australia’s estimate of incident hepatitis B infections involves the use of a simple multiplying factor applied to notifications made to the National Notifiable Diseases Surveillance System (NNDSS) and mathematical models to estimate incident infections. The uncertainty regarding the multiplier for Australia or components of the Australian population leaves mathematical modelling as the recommended methodology.

**Incidence of hepatitis B**

The estimates presented were derived from a deterministic compartmental mathematical model of hepatitis B virus infection in the Australian population from 1951-2050 developed by the Epidemiology Unit, WHO Regional Reference Laboratory for Hepatitis B, Victorian Infectious Diseases Reference Laboratory. The model was parameterised using a wide range of data sources including the ABS, existing mathematical models, surveillance notifications, epidemiological research and clinical studies. Important factors such as migration, attributable and all-cause mortality, the ageing of the population, the variable natural history of chronic HBV infection and the impact of vaccination were all incorporated.

Model construction included sensitivity analyses around critical parameters such as the force of infection (FoI) and migration estimates. Both static and dynamic FoI models were created, the latter using novel techniques for deriving the FoI over time. Model outcomes have been validated using a range of external data, particularly national and Victorian serosurvey results. These were not used to parameterise the model to allow independent comparison with modelled
outcomes, and the 2nd National Serosurvey \(^5\) was also incorporated in generating the plausible range around estimates of hepatitis B prevalence from the model.

According to the hepatitis B model, between 1530 and 2600 incident cases of hepatitis B were estimated to have occurred in Australia in 2010. This range is approximately six to ten times the number of incident hepatitis B infections reported to NNDSS. The modelling suggests that over the past 10 years incidence of hepatitis B infection has moderately declined, by about 10% (Figure 1). The Hepatitis B National BBV and STI Surveillance and Monitoring Plan Working Group recommended the establishment of a Hepatitis B Estimates and Projections Working Group to refine the mathematical modelling estimates.

**Figure 1** Model-based estimate of hepatitis B incidence in Australia

![Graph showing hepatitis B incidence](image)

Coverage of hepatitis B vaccination at 12 and 24 months

Vaccination is the most effective means of preventing the transmission of hepatitis B. Effective implementation of the vaccination program will largely eradicate local transmission. Ideally, a national register of vaccinations that records all vaccine doses administered in all age groups would be used to calculated vaccine coverage. A national register would have captured school-based catch-up immunisation programs undertaken nationally from 1997 that are the likely to be the cause of decreases in local transmission in recent years, and priority populations targeted for adult vaccination in many jurisdictions. Incentivising immunisation may increase vaccination uptake and make it possible to eradicate hepatitis B in these populations \(^6\). Hepatitis B immunisation coverage among infants at both 12 and 24 months of age is excellent across every State and Territory, at ~95% (Figure 2). This level has remained consistently high over time.
Summary:

Although the hepatitis B vaccination program is successfully reaching coverage of approximately 95% among infants, there are still 1530 - 2600 new incident cases of hepatitis B occurring annually. Other evidence suggests this is primarily occurring in priority populations such as people who inject drugs, men who have sex with men, and Indigenous Australians. The weak evidence available suggests that local transmission of hepatitis B is slowly declining.

Reduce the proportion of people with chronic hepatitis B who have not been diagnosed

Monitoring and treatment when appropriate of chronic hepatitis B infection is critical to prevent the long term sequelae; liver cirrhosis, liver failure and hepatocellular carcinoma. The greatest burden of hepatitis B is borne by people with chronic infection. Many of these individuals will have become infected at birth and many are unaware of their infection. Late diagnosis of hepatitis B infection has a significant impact on mortality and morbidity. Therefore, it is important to reduce the proportion of people with chronic hepatitis B who have not been diagnosed.

Estimated proportion of people with chronic hepatitis B who have not been diagnosed

Although large-scale population surveys with serologic testing, including testing of all those entering the population through migration or birth, would constitute the gold standard approach for estimating the true prevalence of hepatitis B infection, this is not currently feasible in Australia. Instead, estimates of undiagnosed infections are currently based on modelling estimates. Although the total number of chronically infected people who are diagnosed can be approximated (particularly in the last 10-15 years for most States and Territories) from the number of unspecified hepatitis B notifications, there is far less certainty about the denominator – the true number of people living with chronic hepatitis B infection in Australia. Regardless, the gap between the number of notifications identified as newly acquired and unspecified hepatitis B cases provide an indication of the extent of undiagnosed chronic hepatitis B infection.
Notifications of newly acquired and unspecified hepatitis

The hepatitis B modelling suggests that over the past 5-10 years the proportion of people with chronic hepatitis B who have not been diagnosed has declined from 55 to 40% (Figure 3).

Figure 3 Model-based estimate of the proportion of people with chronic hepatitis B who have not been diagnosed

Notification data are available for all jurisdictions, with enhanced data collection for newly acquired infections (country of birth, Aboriginal or Torres Strait Islander status) in some jurisdictions. Trends in rates of newly acquired hepatitis B were steadily declining among people in younger age groups over the past 10 years across all jurisdictions (not shown) and both sexes, but notification rates have recently stabilised. However, the total number of notifications in people aged under 30 were stable or declining, showing the effect of school-based catch-up immunisation programs, but those in people aged over 30 had increased since 2004. This increase may reflect either a higher level of testing and/or higher levels of immigration from countries where there is a higher prevalence of hepatitis B. If the increase in notifications is due to changes to immigration patterns, this may also have the effect of increasing the pool of people with undiagnosed chronic infection.
Figure 4  Trends in newly acquired hepatitis B infection, 2001 – 2010, by (A) sex; (B) age group

Figure 5  Trends in unspecified hepatitis B infection, 2001 – 2010, by (A) sex; (B) age group
Proportion of people who die from hepatocellular carcinoma within 12 months of hepatitis B diagnosis

The proportion of people who die from HCC within 12 months of hepatitis B diagnosis is also an indicator of failure to identify and effectively treat chronic hepatitis B. HCC outcome is likely to be worse if it is detected late and symptomatically in someone not known to have chronic hepatitis B, rather than through routine monitoring in someone known to have chronic hepatitis B as a risk factor. Reporting against this indicator is currently not possible but data options will be considered in the next 12 months. The best method of fully enumerating the burden would be a register of all persons with chronic hepatitis B, including their risk factors and need for HCC monitoring. The register could be linked to the national death index or another reporting mechanism that records deaths from HCC.

Summary:
Available evidence for estimating the extent of undiagnosed chronic hepatitis B infection is relatively weak, but suggests that there has not been a substantial change in the level of undiagnosed infections. Estimates suggest approximately 40% of chronically infected hepatitis B cases are undiagnosed.

Improve the health and wellbeing of people with chronic hepatitis B

HCC is one of the major adverse outcomes of chronic hepatitis B infection. Therefore, the number of new hepatitis B-related cases of HCC is an important measure of the hepatitis B disease burden. Increasing the number of people accessing clinical management is imperative to reducing the burden of hepatitis B. Improving the health of people with chronic hepatitis B includes clinical management through antiviral therapy and regular long-term monitoring, including for the development of HCC.

Proportion of people with chronic hepatitis B who are screened 6 monthly for hepatocellular carcinoma

Regular monitoring, every six months, for HCC among people with chronic hepatitis B enables appropriate clinical care and management. Currently there are no systems in place for determining the number of people with chronic hepatitis B who meet the criteria for screening who are screened every six months for HCC. New data collection options will be considered.

Proportion of hepatocellular carcinoma attributable to hepatitis B

As previously stated, the best method of fully enumerating the disease burden would be a register of all persons with chronic hepatitis B. In this instance, the register could be linked to the National Cancer Statistics Clearing House (NCSCH) to determine the number and proportion of HCC cases attributable to hepatitis B infection. As such a registry does not exist, HCC data would need to be collected from the NCSCH or State/Territory cancer registries and retrospectively linked to State/Territory hepatitis B notifications on a routine basis.
Proportion of people with chronic hepatitis B dispensed drugs for hepatitis B infection through the Highly Specialised Drugs Program

The proportion of people with chronic hepatitis B dispensed drugs for hepatitis B infection through the Highly Specialised Drugs (HSD) program is an indication of the extent of access to appropriate therapy. This indicator involves a numerator of number of people receiving therapy and a denominator of the number of people with chronic hepatitis B eligible for antiviral therapy, which can be estimated using modelling. Trends in the numerator, of the number of people dispensed drugs for hepatitis B infection, indicate that the number of people receiving treatment for hepatitis B infection more than tripled from 1247 people in 2004 to 4129 in 2010 (Figure 6) \(^7\). The hepatitis B modelling implies that this means just 2.5% (or about 25% of those eligible based on crude estimates) of Australians living with chronic hepatitis B were dispensed antiviral therapy in 2010.

Figure 6  Number of people dispensed drugs for hepatitis B infection through the highly specialised drugs program

Repeated nationally representative serosurveys of samples of convenience could assist to estimate prevalence of chronic hepatitis B and coupled with mathematical modelling could be implemented to allow projection of prevalence estimates into the future, and to explore trends in the proportion of Australians estimated to be chronically infected with hepatitis B who are being dispensed antiviral medications under the HSD program. Current model-based estimates suggest that there will be a marked increase in the number of hepatitis B-induced liver cancer cases and deaths attributable to hepatitis B under current treatment patterns.

Summary:

No rigorous data are currently available for monitoring the health and wellbeing of people with chronic hepatitis B. New data collection options need to be considered for determining the extent of regular monitoring for HCC and retrospective reviews should be carried out of a random sample of cases of HCC to estimate the attributable fraction of disease associated with hepatitis B.
Hepatitis C

An estimated 297,000 people living in Australia in 2010 had been exposed to the hepatitis C virus, approximately 221,000 of whom were living with chronic infection. Notifications of newly acquired hepatitis C diagnoses to the National Notifiable Diseases Surveillance System in 2010 indicated that hepatitis C transmission continued to occur at the highest rate among adults aged 20-29 years, primarily those with a history of injecting drug use.

The Third National hepatitis C Strategy 2010 – 2013 identified five specific objectives, with associated indicators:

1. **Reduce the incidence of hepatitis C**
   - Annual incidence of hepatitis C in people who inject drugs

2. **Increase access to new injecting equipment through needle and syringe programs**
   - Per capita rate of needles and syringes distributed in the public and pharmacy sector in the previous calendar year
   - Proportion of all injections by people who inject drugs in which a new needle and syringe was used in the previous calendar year
   - Proportion of people who inject drugs reporting re-using another person’s used needle and syringe in the previous month

3. **Reduce the burden of disease attributed to chronic hepatitis C**
   - Estimated number of people with hepatitis C infection by stage of liver disease
   - Self-reported health status by people with hepatitis C

4. **Increase access to clinical care for people with chronic hepatitis C**
   - Proportion of people with chronic hepatitis C dispensed drugs for their infection through the Highly Specialised Drugs Program in the previous calendar year

5. **Reduce hepatitis C-related stigma and discrimination in healthcare settings**
   - Proportion of people with hepatitis C who report discrimination in healthcare settings

Reduce the incidence of hepatitis C

Hepatitis C incidence reflects the current patterns of hepatitis C risk exposures and transmission among a population. The primary risk exposure for hepatitis C acquisition in high income countries is exposure to contaminated blood during injecting drug use. Hepatitis C incidence is most accurately measured prospectively among cohorts of people at risk of infection – namely, PWID - who are documented as hepatitis C antibody negative at entry into the cohort and are followed up at regular intervals to document their hepatitis C status (viraemia and antibody), thereby tracking seroconversions to derive an annual incidence rate based on the observed number of person years at risk.

Annual incidence of hepatitis C in people who inject drugs – cohort studies

The resource implications of conducting prospective observational studies of PWID have led to limited studies in Australia. Two Australian prospective cohorts of PWID are currently maintained via (i) the NSW Hepatitis C Incidence and Transmission – community (HITS-c) study; and (ii) the Victorian Networks Study. HITS-c is a prospective observational study PWID who are hepatitis C antibody negative. Participants are tested for hepatitis C antibody and ribonucleic acid (RNA) every six months and incidence of primary hepatitis C infection is calculated among people completing at least one follow-up visit since enrolment, with date of infection assumed to be the mid-point between the last negative and the first positive test. The Networks study includes prospective follow-up of hepatitis C-infected and -uninfected PWID. Hepatitis C-uninfected participants are tested for hepatitis C antibody and RNA every 3 to 6 months, enabling calculation of the incidence of primary hepatitis C infection as per above.

Annual incidence levels documented by the two studies are depicted in Figures 7a and 7b. In the first two years of the HITS-c cohort, incidence was relatively low at 5.0/100 PY in 2009, increasing slightly to 9.3/100 PY in 2010. Among the Networks cohort, for which hepatitis C incidence estimates are available over a longer period (2006 to 2010), annual incidence estimates were variable, ranging from 3.9/100 PY to 22.2/100 PY. However, it is difficult to determine a trend in incidence either within or between the studies as the confidence intervals overlapped. Estimates derived from HITS-c and Networks are substantially lower than those derived from previous Australian prospective cohort studies, which ranged up to 45.8/100 (95% CI 35.6-58.8), person years among PWID in South-West Sydney in 1999 - 2002.
Figure 7

7A: Annual incidence of hepatitis C in PWID enrolled in prospective observational studies: HITS-c (Sydney)

7B: Annual incidence of hepatitis C in PWID enrolled in prospective observational studies: Networks Study (Melbourne)

Annual incidence of hepatitis C in people who inject drugs - ANSPS

Other data sources can be used to monitor hepatitis C incidence but suffer significant limitations. In particular, the existing passive surveillance system, in which cases of newly acquired hepatitis C infection are notified to NNDSS, fails to capture a large proportion of new infections. Hepatitis C diagnoses may be classified as newly acquired if evidence of acquisition in the 24 months preceding diagnosis is available. However, few notifications (~3-4%) have sufficient supporting data to definitively classify cases in this manner. Significant increased resourcing would be required to identify cases of newly acquired hepatitis C, including high rates of screening of at risk people and rigorous follow-up to identify incident hepatitis C cases in all jurisdictions with limited expected yield.

A rigorous and comparable means of monitoring hepatitis C incidence among PWID could be derived by extending the ANSPS [13] to derive annual estimates of hepatitis C incidence among survey participants based on the proportion who test hepatitis C RNA positive and hepatitis C antibody negative. Conducted annually since 1995, the ANSPS is a serial cross-sectional seroprevalence survey of clients attending needle and syringe programs (NSPs) nationally which uses dried blood spots (DBS) for serological testing to derive annual estimates of HIV and hepatitis C antibody prevalence and associated risk behaviour. The representativeness of ANSPS participants relative to the broader populations of NSP clients has been demonstrated [14]. Groups in the UK [15] and France [16] have recently demonstrated the feasibility of DBS as an alternative to serum specimens for quantifying hepatitis C RNA and genotyping the hepatitis C virus. This study design is considerably less expensive than prospective observational studies and adds value to a rigorous and internationally renowned surveillance mechanism [17]. RNA testing could be conducted annually or biennially. However, the ANSPS is not currently funded to undertake this work and additional resources would be required.

Summary:

Empirical data indicate that hepatitis C incidence ranges between 5 and 22 per 100 person-years among PWID but there is no evidence available that would detect a decreasing or increasing time trend. The large, national, representative samples of PWID recruited by the ANSPS could be used as an additional, consistent, and cost-effective sentinel surveillance method for monitoring hepatitis C incidence through the inclusion of hepatitis C RNA testing in the survey protocol.
Increase access to new injecting equipment through needle and syringe programs

Over the past decade the number of needles and syringes distributed in Australia increased slightly from ~27 million to ~31 million. Saturation of demand for sterile needles and syringes has not been reached [18]. Strategies for improving coverage include expansion of opening hours and the establishment of new NSP outlets as well as relaxation of restrictions on the quantity and range of syringes freely available to NSP clients, the removal of impediments to allow secondary exchange by PWID, and the installation of additional needle and syringe vending machines. Recent research suggest that increasing access to sterile injecting equipment could result in significant reductions in hepatitis C incidence among PWID, averting considerable morbidity and mortality and decreasing associated costs [18].

Rate of needles and syringes distributed in the previous calendar year

The ideal indicator of access to sterile injecting equipment through Australia’s public and pharmacy NSPs – that is, the per capita rate of needles and syringes distributed to people who inject drugs - is not collated. There is currently no routine system by which state and territory health departments report needle and syringe distribution data into a central repository. Individual jurisdictional agreements would be necessary for centralised data collation. In addition, not all jurisdictions have a mechanism to record pharmacy distribution.

To calculate the per capita rate of needles and syringes distributed also requires an estimation of the size of the population of PWID. The Hepatitis C National BBV and STI Surveillance and Monitoring Plan Working Group recommended that the Hepatitis C Virus Projections Working Group [19] be reconvened and, inter alia, construct population size estimations. Currently, no data can be reported against this indicator.

Proportion of all injections by people who inject drugs in which a new needle and syringe was used in the previous calendar year

Needle and syringe coverage is a measure of injecting episodes for which sterile needle and syringes were available. Population-based measures of sterile needle and syringe coverage typically refer to population reach or population access, whereas individual coverage measures typically refer to ‘dosage’ of an intervention [20]. In recent years, an alternative mechanism to calculate individual coverage has been proposed, involving calculating the proportion of injections ‘covered’ by a new needle and syringe for each individual [21].

An extension of the current ANSPS methodology [22] would enable calculation of individual coverage rates for ANSPS participants (approximate N=2,500 each year) and definition of coverage as either adequate (coverage of 100% or more) or inadequate (coverage of less than 100%). The strengths of such methodology include that it would draw on a large, as close to representative as can be achieved, annual cross sectional survey of PWID [21] with the potential to conduct additional analyses to determine factors associated with coverage [21]. The Kirby Institute is to recommend whether to include relevant question module in Australian Needle and Syringe Program Survey every second year, starting 2012. Although minimal additional resources would be required to permit data collection, the proposal would require approval from the ANSPS National Advisory Group and could only be undertaken at the expense of data collection on other issues.

Proportion of people who inject drugs reporting re-using another person’s used needle and syringe in the previous month

Each year, the ANSPS [13] documents the proportion of participants who report re-using another person’s used syringe in the month preceding the survey (Figure 8). In all years between 2001 and 2010, comparable minorities (11%-16%) of ANSPS samples reported receptive needle and syringe sharing (RSS) in the preceding month. Although relatively little variation has been observed in this indicator during the last decade, it is noteworthy that in 1995 (the first year in which the ANSPS was conducted), 29% of participants reported recent RSS (data not shown). However, the data depicted in Figure 8 suggests that the decline has stabilised, with around one in six ANSPS participants each year continuing to report recent re-use of another person’s used needle and syringe.
Summary:

Around one in six PWID who participate in the ANSPS continue to report recent receptive syringe sharing, a proportion that has remained relatively stable since 2001. Measures of needle and syringe program coverage could be built into the ANSPS questionnaire and routinely collected through this mechanism, although this could only occur at the expense of data collections on other issues. To calculate the annual per capita rate of needles and syringes distributed in Australia would require agreement from the health departments of individual jurisdictions, the establishment of a centralised repository for the collation of these jurisdictional data, and regularly updated estimates of the size of the population of people who inject drugs.

Reduce the burden of disease attributed to chronic hepatitis C

To plan appropriate clinical care and treatment responses to the hepatitis C epidemic, accurate estimates of the rates of hepatitis C infection and its sequelae are essential. The epidemiology of hepatitis C in Australia, combined with the natural history of hepatitis C infection, suggests that hepatitis C-related burden of disease, including advanced liver disease, is likely to increase markedly over the coming years [19].

There are numerous challenges to the assessment of hepatitis C-related burden of disease. Affected populations, such as PWID, Aboriginal and Torres Strait Islander people and migrant populations, may have difficulty accessing clinics and receiving routine clinical services, including referral to specialist care. This is related to both the marginalisation of the primary affected populations and structural/model of care barriers, including the predominance of liver clinics located in tertiary hospital rather than primary care settings [23]. The largely asymptomatic nature of acute hepatitis C infection and early-stage disease progression means that hepatitis C infection and early disease progression may go undiagnosed. There is no national surveillance system for hepatitis C-related presentations at specialist clinics; this would involve collating indicators of disease progression including fibroscan, liver biopsy or other measures, as well as recording treatment uptake by treatment type and linking this to resultant outcomes.
Estimated number of people with hepatitis C infection by stage of liver disease

Key indicators of the burden of chronic hepatitis C infection include estimates of the number of people living with chronic infection by stage of liver disease, including those with chronic hepatitis C infection with stage F0/1 liver disease; those with chronic hepatitis C infection with stage F2/3 liver disease; and those living with hepatitis C-related cirrhosis. Estimates of the number of people living with hepatitis C infection by stage of liver disease are currently obtained through mathematical modelling, which suggests that there is a high and increasing burden of hepatitis C-related morbidity in Australia (Table 1). The Hepatitis C National BBV and STI Surveillance and Monitoring Plan Working Group recommended that these estimates be updated by a reformed Hepatitis C Virus Projections Working Group [19].

Table 1  Estimated average number of people living with hepatitis C infection by year and stage of liver disease (plausible ranges are provided for 2010 only)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total hepatitis C prevalence</td>
<td>271 000</td>
<td>278 000</td>
<td>284 000</td>
<td>291 000</td>
<td>297 000</td>
</tr>
<tr>
<td>Exposed to hepatitis C but not chronically infected</td>
<td>68 500</td>
<td>70 400</td>
<td>72 100</td>
<td>74 000</td>
<td>76 000</td>
</tr>
<tr>
<td>Chronic hepatitis C infection with stage F0/1 liver disease</td>
<td>157 000</td>
<td>160 000</td>
<td>162 000</td>
<td>165 000</td>
<td>168 000</td>
</tr>
<tr>
<td>Chronic hepatitis C infection with stage F2/3 liver disease</td>
<td>40 000</td>
<td>42 000</td>
<td>44 000</td>
<td>46 000</td>
<td>48 000</td>
</tr>
<tr>
<td>Living with hepatitis C-related cirrhosis</td>
<td>5 400</td>
<td>5 600</td>
<td>5 700</td>
<td>5 920</td>
<td>6 100</td>
</tr>
<tr>
<td>Hepatitis C-related liver failure</td>
<td>216</td>
<td>222</td>
<td>229</td>
<td>237</td>
<td>245</td>
</tr>
<tr>
<td>Hepatitis C-related hepatocellular carcinoma</td>
<td>108</td>
<td>111</td>
<td>115</td>
<td>122</td>
<td>122</td>
</tr>
</tbody>
</table>

Self-reported health status by people with hepatitis C

The second indicator of hepatitis C-related burden of disease is the self-reported health status of people living with chronic infection. Self reported health measures multiple health domains, including the physical, psychological, social and functional. The self reported nature of such an indicator and the broad domains that it covers provide an important subjective assessment of the impact of hepatitis C on the lived experiences of those affected. There are currently, however, no data collections available to adequately measure this indicator.

Summary:

Currently, limited rigorous data are systematically collated to allow comprehensive monitoring of hepatitis C-related burden of disease. Modelled estimates suggest that hepatitis C-related burden of disease, including advanced liver disease, is high, with approximately 300 000 people infected with hepatitis C of whom ~6 000 are estimated have hepatitis C-related cirrhosis, leading to about 250 liver failure cases and 120 cases of hepatocellular carcinoma each year. This burden is likely to increase markedly over the coming years. There are currently no data collections available to adequately measure self-reported health status among people living with chronic hepatitis C infection.

Increase access to clinical care for people with chronic hepatitis C

In 2006, the Hepatitis C Virus Projections Working Group [14] estimated that under current combination antiviral treatment scenarios, the numbers of people living with chronic hepatitis C infection and more advanced stage F2/3 liver disease or cirrhosis would increase approximately 40% by 2015. Projections suggested that to decrease the numbers of
people living with chronic hepatitis C and stage F2/3 liver disease or cirrhosis, at least a tripling of the number of people receiving antiviral therapy would be required.

Proportion of people with chronic hepatitis C dispensed drugs for their infection through the Highly Specialised Drugs Program in the previous calendar year.

The proportion of people with chronic hepatitis C dispensed drugs to treat their infection is an important indicator to estimate current treatment coverage and the extent of unmet need for hepatitis C treatment, and to inform the development and refinement of models of care to reduce barriers to treatment among some populations. Monitoring this indicator over time will also help evaluate the effectiveness of interventions or changes in policy and practice designed to facilitate treatment access and improve treatment coverage.

The number of people dispensed antiviral therapy for chronic hepatitis C infection is easily accessible through the HSD Program. Figure 9 displays the number of people dispensed drugs for hepatitis C infection through the HSD Program. The number of people living with chronic hepatitis C for whom treatment would be indicated (the denominator of the indicated proportion) cannot currently be robustly determined. The numerator data (Figure 9) indicate that access to antiviral therapy for chronic hepatitis C has markedly increased since 2004 but recently stabilised. This may be due to the removal of the prerequisite for liver biopsy prior to accessing treatment from 2006. However, the proportion of chronically infected people receiving hepatitis C treatment is very low (based on denominators inferred from Table 1). A further challenge is to establish consensus in relation to who should be recommended for treatment. There is also no systematically recorded data available to determine the characteristics of those receiving treatment to identify potential gaps in the delivery specialist treatment services to sub-populations of those with chronic hepatitis C. For example, from 2008-2010 only 10-12% of PWID participating in the ANSPS report a history of antiviral treatment [13, 25].

Figure 9  Number of people dispensed drugs for hepatitis C infection through the HSD Program, 2004-2010

Summary:

Data suggest that access to antiviral therapy for chronic hepatitis C has almost doubled since 2004 but recently stabilised. However, other evidence shows the proportion of chronically infected people receiving hepatitis C treatment is low at only 10 - 12%.
Reduce hepatitis C-related stigma and discrimination in healthcare settings

Proportion of people with hepatitis C who report discrimination in healthcare settings

Many PWID are reluctant to access health care from conventional providers for reasons which include the stigma and discrimination perceived by this group within healthcare settings[26]. Accessible and acceptable health care is nevertheless essential for this group, including the subpopulation of PWID who suffer chronic hepatitis C infection, many of whom report poor health and low levels of wellbeing [27]. Access to health care has the potential to reduce the personal and social impact of hepatitis C; to support reductions in hepatitis C transmission; to maximise affected people’s access to hepatitis C treatment and support; and to inform the nature and scope of interventions aimed at reducing hepatitis C-related stigma and discrimination within health care settings [28]. However, in order to facilitate access, barriers to access need to be reduced or removed entirely, including the barrier constituted by perceived discrimination. Currently no routine data collections exist from which could be derived robust and comparable indicators of stigma and discrimination among people living with chronic hepatitis C infection.

Many challenges are inherent in the assessment of stigma and discrimination. These include the difficulties of operationalising stigma and discrimination and developing reliable measures that are understood by study participants. The National Centre in HIV Social Research (NCHSR) has recently developed two questionnaires that ask about the experiences of people with HIV who endure stigma and discrimination, especially in health care settings. These have been tested for reliability and have demonstrated face validity but the construct of the validity requires confirmation.

Although it is possible to measure indicators of discrimination, the confounding of injecting drug use with hepatitis C infection means that it is difficult to attribute the aetiology of stigma and discrimination. The NSW Anti Discrimination Board Enquiry into hepatitis C Related Discrimination [29] found that discrimination against people living with hepatitis C infection was a result of the association between hepatitis C and injecting drug use, itself an illegal and highly stigmatised activity, as well as poor knowledge about hepatitis C.

Ideally, the key indicator of hepatitis C-related discrimination and stigma would be collected via national, periodic cross-sectional, community-based surveys that use a stratified sampling frame (e.g. 80% PWID, 10% migrant, 5% iatrogenic, 5% other) to recruit people living with hepatitis C infection at sentinel sites, where data are collected at least annually, and where the survey items about stigma and discrimination are highly reliable and valid.

Summary:

Currently, no routine data collections can be used to derive estimates of the prevalence of hepatitis C-related discrimination and stigma. New data collections are required to allow this indicator to be collated in a rigorous manner that will provide comparable estimates over time. In the interim it may be possible to include carefully selected items in one or more existing periodic surveys targeting people living with hepatitis C infection.
HIV

By the end of 2010, an estimated 21,391 people were living in Australia with diagnosed HIV infection, giving a prevalence of 96 per 100,000 population (or 0.1%). The population rate of HIV diagnosis among males (175 per 100,000 (19,407 cases) was almost 10 times the rate among females (18 per 100,000, 1,984 cases). An estimated 70-80% of people living with HIV were infected through homosexual contact (mostly among gay-identified men), ~15% through heterosexual contact (approximately half of which are among people from high-prevalence countries or their partners), and 3% through injecting drug use. Less than 1% of HIV infections were among children aged less than 15 years.

The Sixth National HIV Strategy 2010 – 2013 identified six specific objectives, with associated indicators:

1. Reduce the incidence of HIV
   - Rate of newly acquired HIV infection
   - Estimated incidence of HIV
2. Reduce the risk behaviours associated with the transmission of HIV
   - Proportion of gay men who have engaged in unprotected anal intercourse with casual male partners in the previous six months
   - Proportion of people who inject drugs reporting re-use of someone else’s needle in previous month
3. Increase the proportion of people living with HIV on treatments with undetectable viral load
   - Proportion of treatment-eligible people living with HIV who are receiving antiretroviral treatment
4. Decrease the number of people with undiagnosed HIV infection
   - Proportion of gay men who have been tested for HIV in the previous twelve months
   - Number of people who inject drugs who have been tested for HIV in the previous twelve months
   - Proportion of cases of newly diagnosed HIV infection that have a CD4 count of < 200 cells/μl
5. Improve the quality of life of people living with HIV
   - Proportion of people with HIV who report their general health status and their general wellbeing to be excellent or good

Reduce the incidence of HIV

HIV incidence indicates the pattern of HIV transmission in a population and is best measured in cohorts of people at risk of HIV infection, who are documented as having a negative HIV antibody test at entry into the cohort and are followed up at regular intervals over time to document their HIV status and track potential seroconversion. If cohorts are sufficiently large, and representative of the population group(s) of interest, then good estimates of incidence can be obtained. However, it is not feasible to recruit, maintain and use such cohorts for estimating incidence in the Australian population.

Rate of newly acquired HIV infection

Reported numbers of diagnoses of HIV are used to monitor the trends of transmission in Australia. However, trends in diagnoses may only reflect trends in incidence if testing is relatively frequent among people at risk of HIV infection. Trends in the subset of HIV diagnoses with evidence of infection occurring in the previous 12 months (based on testing history, primary HIV infection, or from serological assays (BED)) are more reflective of incident cases than all HIV diagnoses, but the numbers also depend on testing patterns among people who have recently acquired HIV. The introduction of routine testing of cases of newly diagnosed HIV infection, using specialised laboratory tests such as the BED capture enzyme immunoassay (BED-CEIA) for detecting incident HIV infection within 180 days of diagnosis, has the potential to provide a more complete indication of recent HIV transmission than does surveillance for newly acquired HIV infection.

Trends in newly diagnosed HIV infection and diagnosed cases of newly acquired infection are presented in Figure 10 and Figure 11, by State/Territory. Across Australia there has been an increase in the rate of HIV diagnosis over the past 10 years, from approximately 3.8 per 100,000 population to 4.7-4.9 per 100,000 population (Age-standardised rate
of newly diagnosed HIV infection, 2001 – 2010, by year and State/Territory (Figure 10). A similar relative increase was observed among the subset of HIV diagnoses with evidence of recently acquired infection (Figure 11). However, rates of diagnoses have remained relatively stable over the four-year period, 2007-2010. Use of the BED-CEIA among cases newly diagnosed in 2010 in NSW, Queensland and Western Australia resulted in a 22% increase in the detection of recent infection over the diagnosed cases of newly acquired infection [8].

**Figure 10**  
**Age-standardised rate of newly diagnosed HIV infection, 2001 – 2010, by year and State/Territory**

Historically, New South Wales has had the highest rate of HIV infection which has slightly decreased in recent years. The largest increases in the rate of HIV diagnoses occurred in Victoria and Queensland. The rates in these States are now similar to the level in New South Wales and the rate of diagnosis in Western Australia is heading towards the levels observed in the three largest States. The rate of HIV diagnoses in Territory has increased moderately in most other jurisdictions, with stable-to-declining trends in South Australia.
Estimated incidence of HIV

A statistical approach called back-projection has been widely used to estimate HIV incidence and the number of undiagnosed infections in numerous international contexts. This methodology has been applied to surveillance data in Australia to estimate HIV incidence [30] (see Figure 12 for incidence estimates for men who have sex with men in Australia). This method confirms that trends in diagnoses reasonably reflect trends in incidence, albeit with a delay, and that HIV incidence in Australia has likely stabilised in recent years following 5-10 years of increases.
Summary:

There is reasonably strong evidence that HIV incidence across Australia has recently stabilised 4.6 per 100,000 population after increasing trends. HIV incidence may be slightly decreasing in a few jurisdictions but continues to increase relatively substantially in Queensland and Western Australia.

Reduce the risk behaviours associated with the transmission of HIV

Dominant risk behaviours are proven to be good indicators of subsequent trends in HIV infection [31]. In Australia, the dominant risk factor for HIV infection is unprotected anal intercourse between men specifically that between casual partners who are not seroconcordant.

Proportion of gay men who have engaged in unprotected anal intercourse with casual male partners in the previous six months

Information available through the GCPS indicates that the proportion of HIV negative men who reported any unprotected anal intercourse with casual male partners in the previous six months was stable at around 20% over the 7 years from 2001 to 2007 and then gradually increased to around 22% in 2009 – 2010 (Figure 13). However, over the last decade, the phenomena of serosorting has emerged among gay men, so some of this increase in unprotected anal intercourse may represent sex between HIV negative partners [32] and therefore not represent a risk of HIV transmission. The extent of HIV antibody testing in the past 12 months among these men increased from 65% in 2001 to 73% in 2005 and to 75% in 2010, indicating recognition of the need to confirm knowledge of HIV status more regularly.
Over the past decade it has been noted that increasing proportions of gay men are adopting non condom-based methods of risk-reduction, such as serosorting (restricting all unprotected anal intercourse to partners of the same HIV status) \([32]\), seropositioning (choosing sexual position based on both partners’ HIV status during unprotected anal intercourse with partners of differing HIV status) \([33]\), withdrawal (not permitting ejaculation in the rectum during unprotected anal intercourse), and use of viral load (permitting unprotected anal intercourse with an HIV-positive partner only when his viral load is undetectable) \([34]\). Each of these strategies differs in relative effectiveness, but use of such strategies appears to account for a proportion of unprotected anal intercourse among gay men that may be increasing \([35, 36]\). These changes in behaviour suggest that the blunt measure of unprotected anal intercourse may not be able to capture changes in the risk of HIV transmission during sexual contact between gay men as reliably or with sufficient detail as might be ideal. The level of detail required to monitor these sorts of changes in behaviour is unlikely to be achieved through the GCPS alone and suggests that supplementary methods of collecting such details may be required.

**Proportion of people who inject drugs reporting re-use of someone else’s needle in previous month**

Monitoring risk behaviours among people who inject drugs is essential to ensure that an HIV epidemic does not emerge among this priority population. Evidence from international settings suggest that if HIV epidemics emerge among people who inject drugs then a bridge is built to facilitate a more general epidemic. Given the proportion of people who report injecting drug use as a major transmission mode among Aboriginal and Torres Strait Islander people, particular attention should be given to this population to ensure escalation among this marginalised population does not occur. The proportion of people who inject drugs seen through the Australian needle and syringe program, who reported having re-used another person’s used syringe has remained stable over the past 10 years at around 13 – 14% (Figure 8).
Summary:

Sexual behavioural risk, measured through the GCPS by reports of unprotected anal intercourse with casual partners, indicated a small increase over the past 10 years from 20% to 22%. Some of this increase is likely to reflect serosorting between men. The extent of sharing of used syringes by people who inject drugs seen through needle and syringe programs is about 13 - 14% and did not change over the past 10 years.

Increase the proportion of people living with HIV on treatments with undetectable viral load

Effective antiretroviral therapy leads to the reduction of viral load to undetectable levels. Suppressed viral load improves the health of persons living with HIV. In addition, suppressed viral load reduces the chance of transmitting HIV infection to other people. In Australia there is no coordinated system for collecting data on all people living with HIV after the time of diagnosis.

Proportion of treatment-eligible people living with HIV who are receiving antiretroviral treatment

To increase the proportion of people living with HIV on treatments with undetectable viral load it is essential to understand the proportion of people living with HIV who are undiagnosed, the proportion who are diagnosed and on antiretroviral treatment and then the proportion of these people who have undetectable viral load (Figure 14). The number of people receiving antiretroviral treatment was estimated from numbers of antiretroviral drugs dispensed for HIV infection through the HSD Program adjusted by the proportion of people monitored through the Australian HIV Observational Database (AHOD) who were prescribed the same drugs (see Methodological notes in [8]).

Figure 14 Estimated proportion of people living with HIV by diagnosis and treatment status, 2010

The estimated number of people dispensed antiretroviral treatment for HIV infection, based on data available through the HSD Program, increased steadily from 7,619 in 2001 to 11,523 in 2010. The estimated number of people living with HIV infection has also increased, from 12,730 in 2001 to 21,391 in 2010. The estimated proportion of people living with HIV infection who were dispensed antiretroviral treatment has remained stable at around 52% over the past...
10 years. The GCPS indicate that the proportion of men with diagnosed HIV infection who report use of antiretroviral treatment has increased from around 63% in the years 2001 to 2005 to 67% in 2006 – 2010. The proportion of men with diagnosed HIV infection in Sydney and Brisbane reporting use of antiretroviral treatment increased from 64% and 55% in 2001 – 2005, to 69% and 66% in 2006 – 2010, respectively, whereas the proportion in Melbourne was stable at around 61% in 2001 - 2010. Use of antiretroviral treatment by men with diagnosed HIV infection in Melbourne, Queensland, and Adelaide, Canberra and Perth combined, had also increased to approximately 70% in 2010.

Proportion of people receiving antiretroviral treatment for HIV infection whose viral load is less than 50 copies/mL

AHOD is a cohort containing a relatively large number of people living with HIV in Australia, recording data on viral load among people receiving antiretroviral therapy. It measures the proportion of people living with HIV in clinical care who have undetectable viral load but it should be noted that the cohort may not be representative of all people living with HIV in Australia, particularly since it is an ageing cohort. Greater recruitment of people newly diagnosed with HIV infection into the cohort would be valuable.

The proportion of people enrolled in AHOD whose viral load was less than the specified assay sensitivity (50 copies/ml and 400 copies/ml) increased from 39% and 67%, respectively, in 2000, to 83% and 94%, respectively, in 2010 (Figure 15).

**Figure 15** HIV viral load and CD4+ cell count, 2001 – 2010, by year

Summary:

There is a steady increase in the number of people dispensed antiretroviral treatment for HIV infection over the past ten years. However, the estimated proportion (52%) of people living with HIV infection who were dispensed antiretroviral treatment does not appear to have changed over this period from the relatively high baseline levels. The extent of viral suppression among people on ART has substantially increased over this period to ~80%. Taken together, the proportion of people living with HIV on treatments with undetectable viral load has substantially increased.
Decrease the number of people with undiagnosed HIV infection

There is a critical role for effective and timely HIV antibody testing for minimising ongoing HIV transmission, minimising the morbidity and mortality caused by HIV, minimising the personal and social impact of HIV infection, and for more accurate population-level surveillance. Late HIV diagnoses leads to late initiation of antiretroviral treatment for minimising the risk of progression of HIV disease and for minimising the risk of onwards HIV transmission. A pilot study conducted among gay men in Melbourne found that 31% (95% CI 20%-44%) of HIV infections in this sample were unrecognised. This is substantially higher than previously believed levels of undiagnosed HIV infections in Australia.

The dominant routes of HIV transmission in Australia are homosexual contact through anal intercourse, heterosexual through vaginal and anal intercourse, and to a small extent injecting drug use. Levels of undiagnosed infections would differ between these population groups and therefore different measures of undiagnosed infections should be obtained for each group. Currently, there is not a mechanism for collecting data on undiagnosed infections or testing rates among the general heterosexual population. However, data do exist for estimating testing rates among gay men and people who inject drugs. In addition, the extent of late HIV diagnosis can be inferred based on cases which have a CD4 count less than 200 cells/μl around the time of first diagnosis. Information on CD4+ cell count is routinely collected at notification of newly diagnosed HIV infection in all State/Territory health jurisdictions in Australia.

Proportion of gay men who have been tested for HIV in the previous twelve months

HIV antibody testing reported in the last 12 months by men participating in the GCPS who had not been diagnosed with HIV infection increased from 56% in 2001 to 63% in 2007 and declined to 57% in 2010 (Figure 16). Among men who had had at least 10 male sexual partners in the previous 6 months, HIV antibody testing in the previous 12 months increased from about 67% in the five years from 2001 to 2005 to around 75% in the years from 2006 to 2010. HIV antibody testing within the previous 12 months also increased from around 61% in the years 2001 to 2005, to 64% in the years 2006 to 2010 among men who had not been diagnosed with HIV infection and who reported any unprotected anal intercourse with casual partners. Levels of undiagnosed infections could be estimated more directly by supplementing GCPS data collection with the inclusion of saliva or dry blood spot collections for HIV testing.

Figure 16 Men without diagnosed HIV infection participating in the GCPS, who tested for HIV antibody in the 12 months prior to the survey, by year and city
Number of people who inject drugs who have been tested for HIV in the previous twelve months

The proportion of participating in the ANSPS who reported having had an HIV antibody test in the previous 12 months declined from 61% in 2001 to 48% in 2010 (Figure 17). The decline in recent HIV antibody testing may be associated with the change in the age structure of PWID in Australia.

The proportion of ANSPS participants aged less than 20 years dropped from 7.2% in 2001 to 1.4% in 2010, and the proportion aged 35 years and older increased from 32% in 2001 to 59% in 2010. HIV prevalence was highest among people aged 35 years and older.

Proportion of cases of newly diagnosed HIV infection that have a CD4 count of < 200 cells/µl

Among cases of newly diagnosed HIV infection with a reported CD4+ cell count, the proportion whose CD4+ cell count was less than 200 cells/µl remained stable at around 21% over the past ten years, 2001 – 2010 (Figure 18). The proportion with a late HIV diagnosis was lowest among MSM at 16% but they account for 52% of late diagnoses. Late HIV diagnosis was highest at around 35% among cases from a high prevalence country and cases with an undetermined exposure. The proportion of new HIV diagnoses for which the CD4+ cell count was not reported dropped from 25% in 2001 to 11% in 2010, resulting in a more reliable estimate of the extent of late HIV diagnosis in recent years.
Summary:

There is mixed evidence about the extent and trends in undiagnosed HIV infections in Australia. Men participating in GCPS who report high numbers of sexual partners, or unprotected anal intercourse with casual partners, have reported increasing rates of HIV testing. However, reported testing rates have fluctuated among all gay men. There have been substantial decreases in the reported HIV testing rates among people who inject drugs seen through needle and syringe programs. However, the distribution of CD4 counts at diagnosis has not markedly changed over time. Overall, there is inconclusive evidence about trends in undiagnosed HIV infections with some indications that the level may be increasing.

Improve the quality of life of people living with HIV

Within the goal of the Sixth National HIV Strategy is the aim to minimise the personal and social impact of HIV infection. The National Strategy also identifies, through the guiding principles and priority areas for action, the need to tackle stigma, isolation, mental health and other social impacts of HIV infection. These quality of life indicators cannot be easily measured by biomedical indicators.

Proportion of people with HIV who report their general health status and their general wellbeing to be excellent or good

Currently, the Futures study is the only regular cross-sectional study of the experiences of people living with HIV nationally for which there exists a baseline and trends, and it is from this study that a general indicator has been derived to report on the quality of life of people living with HIV. Specifically, the proportion of people with HIV who report their general health status and their general wellbeing to be excellent or good in the Futures study has been identified as a measurable indicator for characterising the perceived quality of life of people living with HIV. This measure is intended to complement the clinical indicators related to people living with HIV to provide a broad indication of the morbidity and the social impact of HIV infection.
The HIV Futures Study is conducted every 2-3 years and is a national cross-sectional survey of people living with HIV. HIV Futures 6 was the latest of these anonymous self-administered surveys to be completed, sampling 1106 people living with HIV infection in Australia [40]. The survey was carried out over 7 months from October 2008 to April 2009.

Among people living with HIV infection who participated in HIV Futures 6 survey, 72% of respondents reported their health as ‘good’ or ‘excellent’. Self rating of wellbeing was monitored in 4 surveys from 2001 to 2008–2009 and ‘wellbeing’ was reported as ‘good’ or ‘excellent’ by 60–72% of respondents across previous surveys.

It is recognised that the current indicator is not a comprehensive measure of quality of life or social impact of PLHIV. However, it does generally correlate well with a range of other health and wellbeing indicators [40].

**Summary:**

Perceived quality of life of people living with HIV appears to have slightly increased, with close to three-quarters reporting their health as ‘good’ or ‘excellent’.
Sexually Transmissible Infections

STIs affect large proportions of Australia’s population, with infections affecting different population groups. Chlamydia has been the most frequently reported notifiable disease in Australia for the past 10 years, predominantly affecting young heterosexual people (aged 15-30 years) among whom prevalence is approximately 4% [41, 42]. Gonorrhoea infection is most common among young people but more frequently observed among males than females, reflecting epidemics related to both heterosexual transmission in Aboriginal and Torres Strait Islander people and male homosexual transmission. Syphilis infection is currently predominantly affecting (HIV-positive) males aged 20-40 years, reflecting an epidemic among men who have sex with men. Aboriginal and Torres Strait Islander people are disproportionately affected by all sexually transmissible infections.

The Second National Sexually Transmissible Infections Strategy 2010 – 2013 identified six specific objectives, with associated indicators:

1. Reduce the incidence of gonorrhoea
   - Annual rate of notifications of gonorrhoea
   - Incidence of gonorrhoea
2. Reduce the incidence of infectious syphilis
   - Annual rate of notifications of infectious syphilis
   - Incidence of infectious syphilis
3. Reduce the incidence of chlamydia
   - Proportion of Chlamydia tests that yield a positive result
   - Incidence of chlamydia
4. Increase testing for chlamydia among priority populations
   - Proportion of 16 to 25 year olds receiving a chlamydia test in the previous 12 months
   - Proportion of STI tests in gay men that give a positive result
   - Proportion of gay men who report having had an STI test in the previous 12 months
5. Increase young people’s knowledge of STIs
   - Proportion of secondary school students giving correct answers to STI knowledge questions
6. Incorporate STI-related prevention and treatment into broader health reforms
   - Proportion of 16 to 25 year olds who undergo a chlamydia test in general practice

Reduce the incidence of gonorrhoea

Annual rate of notifications of gonorrhoea

Notifications of gonorrhoea are used to monitor the trends of transmission in Australia. However, trends in diagnoses may only reflect trends in incidence if testing is relatively frequent among people at risk of infection and testing rates do not change substantially over time. Over the past 10 years, national notifications for gonorrhoea increased by almost 25% from 33.5 to 43.5 cases per 100 000 population. This increased pattern was observed by most jurisdictions. However, differences were observed in the Northern Territory and Western Australia where peaks were reached in 2005 and 2007, respectively, with subsequent declines. Notifications in the Northern Territory subsequently rebounded in 2010 (Figure 19).
For non-Indigenous people, the notification rate in men is more than twice the rate in women (Figure 20). The notification rate in Aboriginal and Torres Strait Islander people is more than 26 times higher than non-Indigenous people (Figure 21) and increased 21% to 804 per 100,000 population. There were few notifications in non-Indigenous women. This indicates a two pronged epidemic in Aboriginal and Torres Strait Islander people resident in remote communities and men who have sex with men resident in urban areas. Gonorrhoea notifications steadily increased in men who have sex with men over the past ten years whereas gonorrhoea had been steady or declining in the Northern Territory, Queensland, South Australia and Western Australia for the four years prior to 2010. In 2010, this rate increased in all jurisdictions, except Western Australia.

Incidence of gonorrhoea

Notification data is a convenient measure of incidence, but it lacks a natural denominator and is therefore heavily influenced by changes to patterns of testing. Evidence from indicators on STI testing later in the report suggests that some tests for bacterial STIs have increased in gay men over the last 10 years, which may account for the increased rate of notification. There is no indication of current trends in testing in Aboriginal communities.

As suggested by the STI National BBV and STI Surveillance and Monitoring Plan Working Group, a better measure of incidence would be sentinel surveillance conducted in populations identified as being at risk. Sentinel surveillance has the advantage of having both a numerator and a denominator. Currently, there is no national sentinel surveillance system for gonorrhoea routinely collected in Australia, but a comprehensive national indicator would involve the inclusion of the sexual health clinic, Aboriginal community controlled health service and laboratory networks. Other data will become available for Aboriginal and Torres Strait Islander people from studies such as STI in Remote communities: ImproVed & Enhanced primary health care (STRIVE), currently being conducted in 67 remote communities spanning three jurisdictions of the Northern Territory, Queensland and Western Australia.
Figure 20  Gonorrhea notifications, 2001 – 2010, by year and sex

Figure 21  Number of diagnoses of gonorrhoea in 2010 by Aboriginal and Torres Strait Islander status, sex and age group
Summary:

Gonorrhoea is a two pronged epidemic. The available evidence for gonorrhoea incidence suggests that incidence may be increasing for men who have sex with men, with the notification rate in men increasing 26% to over 60 per 100,000 population. The same evidence suggests that incidence in Aboriginal and Torres Strait Islander people that had been declining increased in 2010 to 804 per 100,000 population.

Reduce the incidence of infectious syphilis

Annual rate of notifications of infectious syphilis

Incidence of syphilis is measured by the surrogate marker of number of notifications of early syphilis. The case definition for syphilis changed in 2004, which means notification data for infectious syphilis or syphilis of less than two years duration is only available from that date. National notifications for infectious syphilis more than doubled from 3.1 to 6.7 cases per 100,000 between 2004 and 2007 after which they have slowly declined but at higher levels than the baseline of 2004 (Figure 22).

This increase in infectious syphilis was entirely among men, reflecting an epidemic in men who have sex with men (Figure 23), most of who were gay-identified men. This pattern of notification was seen in all jurisdictions but the Northern Territory. The substantial increase in infectious syphilis notifications among men masked declines in infectious syphilis cases among Aboriginal and Torres Strait Islander people in Queensland and Western Australia. Unlike other bacterial STIs the notification rate was highest in people aged 30 – 39 years for non-Indigenous peoples (Figure 24). Notifications in Aboriginal and Torres Strait Islander people occur at five times the rate of non-Indigenous people and outbreaks in remote communities continue to occur.
Notification data lacks a natural denominator and is therefore heavily influenced by changes to patterns of testing. However, evidence from the indicator in STI testing in gay men discussed later in the report suggests that blood testing for STI other than HIV has remained stable in gay men over the last 10 years.
Incidence of infectious syphilis

For reasons already mentioned in the previous section on gonorrhoea incidence, sentinel surveillance conducted in populations identified as at risk would be a better measure of syphilis incidence. Currently, there is no national sentinel data for infectious syphilis routinely collected in Australia, but a comprehensive national indicator would involve the inclusion of the sexual health clinic, Aboriginal community controlled health service and laboratory networks as a minimum. Other data sources suggest HIV-positive men are at higher risk of syphilis infection. It would therefore be worth adding some clinics with a high HIV caseload to the general practitioner network. As mentioned previously, the STRIVE project will be an important source of testing data in remote Aboriginal communities.

Summary:

The available evidence for infectious syphilis incidence suggests that syphilis in men who have sex with men is currently declining to 4.9 per 100 000 population after reaching 6.7 in a large resurgence in previous years. The same evidence shows there are continuing outbreaks in Aboriginal communities.

Reduce the incidence of chlamydia

Proportion of Chlamydia tests that yield a positive result

Unlike other STIs, testing data are available for chlamydia from Medicare. The number of chlamydia notifications increased 4-fold between 2001 and 2010 and there was an 8-fold increase in the number of chlamydia tests carried out through Medicare over the same period (Figure 25). The proportion of all tests that were positive for chlamydia decreased by more than half from 21% in 2001 to ~9% in 2007, stabilising for three years and increased for the first time in 2010. These data likely reflect a large pool of undiagnosed infections; insufficient screening rates relative to the level of infection in the population and transitions from chlamydia testing primarily in high-risk populations towards more widespread testing in the general population makes it difficult to draw conclusions about trends in incidence of new chlamydia infections.

Figure 25  Number of notifications and number of tests for chlamydia, 2001 – 2010, by year and sex

<table>
<thead>
<tr>
<th>YEAR</th>
<th>NOTIFICATIONS</th>
<th>TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2002</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2003</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2004</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2005</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2006</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2007</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2008</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2009</td>
<td>100000</td>
<td>100000</td>
</tr>
<tr>
<td>2010</td>
<td>100000</td>
<td>100000</td>
</tr>
</tbody>
</table>
The proportion of tests positive for chlamydia was greater in men than in women as would be expected since the number of tests conducted in men was less than half the number conducted for women (Figure 26). The proportion of tests that were positive was highest in people aged 15 – 24 years of age and the 2010 increase was also higher in this group than in older age groups (Figure 27).

Figure 26 Proportion of positive chlamydia tests, 2001 – 2010, by year and sex

Figure 27 Proportion of positive chlamydia tests, 2001 – 2010, by year and age group

1 Medicare testing data was not available between November 2005 and May 2007. Chlamydia notification data was excluded from the calculations for this period as well.
Incidence of chlamydia

Another measure of the extent of chlamydia infections is the pattern of positivity at sentinel surveillance sites. Sentinel surveillance has the advantage of having both a numerator and a denominator. A disadvantage may be its lack of representativeness of the broader population. The ACCESS study is a sentinel surveillance network that collects data on the uptake and outcome of chlamydia testing in Australia through six networks. Currently it is in maintenance mode as it is not funded, with only three networks able to report data. Data from first-time sexual health clinic attendees, a high risk population, has revealed an increase in chlamydia positivity across all priority populations between 2007 and 2010 (Figure 28). The largest increase was in Aboriginal and Torres Strait Islander males and females where positivity rates increased from 12.7 to 20.7% and 15.1 to 20.7%, respectively. Positivity levels also increased in heterosexual men and women, men who have sex with men, and sex workers to 15.6, 16.3, 9.1 and 5.6% respectively in 2010.

![Figure 28 Chlamydia positivity rate, 2007 – 2010, by year and chlamydia priority population](image)

**Summary:**

The available evidence for chlamydia incidence is weak, but suggestive that incidence is likely to be slightly increasing. Positivity levels increased by more than 5% in Aboriginal and Torres Strait Islander people and young heterosexual women, and lesser amounts in other priority groups. The proportion of chlamydia tests that were positive increased for the first time in 2010, with a 1% increase to 15.1% in people aged 15-24 years. It is too early to determine whether this is part of a continuing trend.
Increase testing for chlamydia among priority populations

Testing people for sexually transmissible infections reduces the pool of people at risk of transmitting an infection by allowing them to be treated and cured or to modify their sexual behaviour to prevent transmission to others. Increasing the frequency of testing is therefore a prime mechanism for reducing incidence, particularly when applied to high risk populations.

Proportion of 16 to 25 year olds receiving a chlamydia test in the previous 12 months

The proportion of people aged 15 – 24 years receiving a test for chlamydia in the previous 12 months increased substantially between 2001 and 2010 (Figure 29). While there was an increase for both men and women, it was greater for women than for men. While it is clear from the available data that there was a marked increase in chlamydia testing during the period, the precise magnitude of the increase is unknown with up to 10% of young people tested in 2010. This is due to some uncertainty surrounding the Medicare testing data: there was a change in the collection of Medicare data for chlamydia in November 2005 when item numbers relating to chlamydia were removed from the Medicare schedule, reinstated in May 2007 but with different item numbers leading to imperfect matching between the two periods. Repeat tests are included in this dataset. Repeat testing will artificially inflate the proportion of people tested, but current evidence suggests that the rate of repeat testing is low [46].

Figure 29 Proportion of 15-24 year olds receiving a chlamydia test in the previous 12 months, 2001 – 2010, by year and sex

<table>
<thead>
<tr>
<th>YEAR</th>
<th>PERCENTAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>0</td>
</tr>
<tr>
<td>2002</td>
<td>2</td>
</tr>
<tr>
<td>2003</td>
<td>5</td>
</tr>
<tr>
<td>2004</td>
<td>7</td>
</tr>
<tr>
<td>2005</td>
<td>10</td>
</tr>
<tr>
<td>2006</td>
<td>15</td>
</tr>
<tr>
<td>2007</td>
<td>20</td>
</tr>
<tr>
<td>2008</td>
<td>25</td>
</tr>
<tr>
<td>2009</td>
<td>30</td>
</tr>
<tr>
<td>2010</td>
<td>35</td>
</tr>
</tbody>
</table>

1 Medicare testing data was not available between November 2005 and May 2007. Chlamydia notification data was excluded from the calculations for this period as well.

Proportion of STI tests in gay men that give a positive result

The only sentinel surveillance data currently available for men who have sex with men comes from the ACCESS study, a sentinel surveillance network that collects data on the uptake and outcome of chlamydia testing in Australia through six networks. Data from first-time sexual health clinic attendees found a slight increase in chlamydia testing in men who have sex with men between 2007 and 2010 (Figure 30). Men who have sex with men had a mid-range rate of testing compared to other population groups of interest with 89% being tested at their first visit.
Figure 30  Chlamydia testing rate, 2007 – 2010, by year and chlamydia priority population

Proportion of gay men who report having had an STI test in the previous 12 months

Self reported data on STI testing in the past 12 months in gay men is collected annually as part of the GCPS. The proportion of gay men reporting any STI testing in the past 12 months increased marginally from 63.6% in 2001 to 65.5% in 2010. There was a more marked increase in bacterial STI testing at all genital sites, including pharyngeal and urine testing, but the proportion of tests done started from a lower base. Despite the resurgence of syphilis infections, the proportion of men receiving a blood test for an STI other than HIV remained stable (Figure 31). It is important to note that these data are based on self-reporting and participants may not recall the exact nature or timing of a specific test. This national set of data combines data from different States and Territories. In each State and Territory, the surveys are conducted at different local events and not all the surveys are conducted annually. This may be responsible for some of the difference in trends.
Summary:

There has been a substantial increase in the rate of chlamydia testing among young people aged 15 – 24 years in Australia over the past 10 years with up to 10% of young people tested in 2010. The rate of testing in men who have sex with men is approximately 65% and has not increased over this same timeframe, but the increase in some types of tests suggests that STI testing has become more comprehensive.

Increase young people’s knowledge of STIs

The provision of information to populations at risk of STIs may help reduce the incidence of infection by enabling the reduction of risk behaviour. In particular, exposure to information on methods of transmission, prevention and treatment will help individuals when making specific behaviour choices. The delivery of age-appropriate education within the school curriculum is seen as the best mechanism for improving young people’s STI knowledge.

Proportion of secondary school students giving correct answers to STI knowledge questions

Information on young people’s STI knowledge is available from the Survey of Secondary Students and Sexual Health [47]. The survey is conducted by the Australian Research Centre in Sex, Health and Society approximately every five years with the most recent survey being held in 2008. The survey is conducted among students in both Year 10 and Year 12; the trend among Year 10 students is used here.

Knowledge about STIs is generally poorer than HIV knowledge with the students achieving a mean HIV knowledge ‘score’ of 9.2 compared to a mean STI knowledge ‘score’ of 6.9. STI knowledge improved between the 2002 and 2008 surveys, but it is not very comprehensive with only about 5% of male and female students giving correct answers to all STI knowledge questions in the survey in 2008 (Figure 32). There was no discernable difference in the level of knowledge between young males and females.
However, there have been improvements in specific areas. Encouragingly, almost 90% of young people understand that a person can have an STI without exhibiting symptoms and about 75% know that condoms do not protect against all STIs. However, more than 50% believe that chlamydia is an infection that only affects women and that genital herpes is curable. Less than 50% of students understand that gonorrhoea can be transmitted via oral sex and that genital warts can be spread by any skin to skin contact.

Summary:
STI knowledge among young people has improved over time, but the level of knowledge is variable and generally low.

Incorporate STI-related prevention and treatment into broader health reforms

As chlamydia infection is so widespread in people aged 15 - 29 within the general population \[^{41,42}\], interventions targeted toward specific populations will not be very effective at reducing infection at a larger population-level. STI treatment and prevention should therefore become part of routine care for young people when they present for other health care. The proportion of individuals tested for chlamydia in general practice (GP) is one way to measure the effectiveness of integration of STI prevention and treatment into broader healthcare.

Proportion of 16 to 25 year olds who undergo a chlamydia test in general practice

The proportion of chlamydia tests carried out for every GP consultation increased from less than 1 test per 100 GP visits to 3.5 tests per 100 visits to a GP clinic (Figure 33). This increase was fairly uniform across State and Territory health jurisdictions. There was a difference in the proportion of tests by sex, with almost twice as many tests being conducted in women compared to men by 2010 (Figure 34). Women’s higher morbidity as a result of undiagnosed chlamydia may result in more opportunistic screening by clinicians. Women are also more likely to present at GP clinics due to better engagement with health services.
Figure 33  Proportion of people aged 15-24 receiving a chlamydia test in a general practice visit, 2001 – 2010, by year and State/Territory

Figure 34  Proportion of people aged 15-24 receiving a chlamydia test in a general practice visit, 2001 – 2010, by year and sex

Summary:

There is evidence that STI treatment and prevention has become more integrated into broader healthcare to some extent. The proportion of chlamydia tests carried out for every GP consultation has increased over the past 10 years from less than 1 to 3.5 tests per 100 GP visits. This increase has been more marked in women than in men.
Aboriginal and Torres Strait Islander Blood-borne Viruses and STIs

Aboriginal and Torres Strait Islander communities face substantial public health issues and challenges around BBVs and STIs including sustained and unacceptable high rates of STIs and high rate of acquisition of HIV and hepatitis C through injecting drug use.

The Third National Aboriginal and Torres Strait Islander Blood-borne Viruses and Sexually Transmissible Infections Strategy 2010 – 2013 identified seven specific objectives, with associated indicators:

1. **Reduce hepatitis B infections**
   - Coverage of hepatitis B vaccination at 12 and 24 months

2. **Work towards eliminating infectious syphilis in Aboriginal and Torres Strait Islander people**
   - Rate of infectious syphilis notifications among Aboriginal and Torres Strait Islander people
   - Rate of syphilis testing among Aboriginal and Torres Strait Islander people in remote areas

3. **Decrease the proportion of HIV and hepatitis C infection caused by injecting drug use**
   - Proportion of Aboriginal and Torres Strait Islander people who are notified as newly diagnosed with HIV who report injecting drug use
   - Incidence of newly diagnosed hepatitis C infection in Aboriginal and Torres Strait Islander people

4. **Increase the level of testing and treatment of sexually active 15-30 year olds**
   - Proportion of Aboriginal and Torres Strait Islander young people who report having had an STI test in the previous 12 months
   - Rate of chlamydia tests in remote areas in NT, Qld, SA, WA in the previous 12 months
   - Proportion of Aboriginal and Torres Strait Islander young people receiving a chlamydia and gonorrhoea test in the previous 12 months

5. **Improve Aboriginal and Torres Strait Islander people’s knowledge of STIs and BBVs**
   - Proportion of Aboriginal and Torres Strait Islander people giving correct answers to knowledge questions on STIs and BBVs

6. **Increase the number of Aboriginal and Torres Strait Islander peoples receiving treatment for HIV, hepatitis C and hepatitis B**
   - Proportion of Aboriginal and Torres Strait Islander people with HIV receiving antiretroviral treatment
   - Proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis C who are dispensed drugs for hepatitis C infection through the Highly Specialised Drugs Program in the previous 12 months
   - Proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis B who are dispensed drugs for hepatitis B infection through the Highly Specialised Drugs Program in the previous 12 months

7. **Implement a national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers**
   - Number of Aboriginal and Torres Strait Islander people registered under the National Registration Program

**Reduce hepatitis B infections**

Infection with hepatitis B virus remains a significant health burden in Aboriginal and Torres Strait Islander communities. In 2007, 2.5% of the Australian population identified as Aboriginal or Torres Strait Islander but accounted for an estimated 16% of the Australian population living with chronic hepatitis B infection.

New diagnoses of hepatitis B and newly acquired hepatitis B are notifiable conditions in all State/Territory health jurisdictions in Australia, to the National Notifiable Diseases Surveillance System. Greater than 50% of diagnoses for newly acquired hepatitis B were notified by Aboriginal and Torres Strait Islander status for all jurisdictions in 2010. In 2010, the diagnosis rate for newly acquired hepatitis B infection in the Aboriginal and Torres Strait Islander population...
was four times higher than in the non-Indigenous population in Australia. In Aboriginal and Torres Strait Islander communities, it is estimated that the prevalence of hepatitis B is 2% in urban areas and 8% in rural areas. Prevalence levels are likely to be higher in remote Aboriginal and Torres Strait Islander communities.

**Hepatitis B immunisation coverage among Aboriginal and Torres Strait Islander children at 12 and 24 months**

Hepatitis B vaccination, including universal infant vaccination, is the most effective prevention measure for hepatitis B. Effective implementation of the vaccination program will largely eradicate transmission and the sequelae of infection. It would be ideal to utilize a national register of vaccinations that records all courses in all age groups to calculate vaccine coverage. High reporting of Aboriginal and Torres Strait Islander status would also be of value for the purpose of evaluation of vaccination coverage in this population. Currently, there appears to be some under-reporting to the infant vaccination register in some Australian jurisdictions and the absence of a vaccination register for adolescents. Between 2006 and 2010, hepatitis B immunisation coverage among Aboriginal and Torres Strait Islander infants at 12 months of age was good across every State and Territory. It improved over time from an average of 83 to 85% but was lower than for non-Indigenous infants (Figure 35 & Figure 2). By 24 months of age, hepatitis B vaccination coverage had improved and was excellent, equalling the coverage in non-Indigenous infants at between 90 and 95% (Figure 36).

**Figure 35** Hepatitis B immunisation coverage among Aboriginal and Torres Strait Islander infants at 12 months, 2010, by State/Territory
Summary:
Hepatitis B infection rates are substantially higher among Aboriginal and Torres Strait Islander communities than among non-Indigenous Australians. Vaccination coverage is excellent among infants at over 90% for children at 24 months of age.

Work towards eliminating infectious syphilis in Aboriginal and Torres Strait Islander people

Rate of infectious syphilis notifications among Aboriginal and Torres Strait Islander people

Accurate and complete systems exist nationally for the notification of infectious syphilis; diagnoses have been reported nationally since 2004 to the National Notifiable Diseases Surveillance System. Greater than 95% of all infectious syphilis diagnoses have been notified by Aboriginal and Torres Strait Islander status. Reported numbers and rates of diagnoses of infectious syphilis in Aboriginal and Torres Strait Islander people are used to monitor trends of transmission in this population.

After an increase between 2004 and 2006 in the reported number of infectious syphilis diagnoses in the Aboriginal and Torres Strait Islander population, the number of diagnoses declined from 234 in 2006 to 130 in 2010. The population rate of diagnoses of infectious syphilis decreased from 40 in 2006 to 25 per 100 000 in 2010 (Figure 37), however this rate was still 5 times greater than the rate reported in the non-indigenous population (5 per 100 000 in 2010) (Figure 37). Continuing outbreaks of syphilis occurring in remote Aboriginal communities will need to be acted upon to ensure this goal can be achieved over the longer term.
There are stark differences in rates and trends in infectious syphilis between the States and Territories (Figure 38). Tasmania has not had a reported case of infectious syphilis in the Aboriginal and Torres Strait Islander population since 2004. The rate of infectious syphilis in NSW has been relatively stable since 2004 (6.4 per 100,000 in 2010) and similar to the non-Indigenous population (6 per 100,000 in 2010). The largest declines were seen in Victoria and the Northern Territory. The rate in Victoria decreased from 27 in 2008 to 3.8 per 100,000 in 2010, dropping below the rate in non-Indigenous Victorians (5 per 100,000 in 2010). The rate in the Northern Territory dropped from 178 in 2006 to 70 per 100,000 in 2010; however this is still 40 times greater than the rate in the non-Indigenous population. Finally, there has been an increase in the rate of infectious syphilis in Queensland between 2008 and 2010, rising from 16 to 35 per 100,000.

Rates of infectious syphilis diagnoses in the Aboriginal and Torres Strait Islander population decreased in major cities, inner regions, remote and very remote regions from 2004 to 2010 but increased between 2006 and 2010 in outer regional areas of Australia (22 to 39 per 100,000). The rate of infectious syphilis in outer regional, remote and very remote areas of Australia were greater than that in major cities and inner regions, and were 14, 49 and 10 times greater than the rate of infectious syphilis among non-Indigenous people residing in the same areas (Figure 39).
Figure 38  Rate of infectious syphilis, 2004 – 2010, by Aboriginal and Torres Strait Islander status and State/Territory

Figure 39  Rate of infectious syphilis, 2004 – 2010, by Aboriginal and Torres Strait Islander status and area of residence
Rate of syphilis testing among Aboriginal and Torres Strait Islander people in remote areas

These reported trends in diagnoses may only reflect trends in incidence of infectious syphilis if testing is relatively frequent. Since high rates of syphilis are observed in remote and very remote areas, an increase in syphilis testing among Aboriginal and Torres Strait Islander people in these areas is a significant step forward to 1) allow the rates of diagnoses to correctly reflect incidence trends and 2) diagnose and subsequently treat those in the community with infectious syphilis to prevent further transmission. Syphilis testing data are currently unavailable. It is recommended that jurisdictions negotiate with pathology providers to access syphilis testing data with a focus on the Northern Territory, Western Australia, Queensland and South Australia, with remote areas to priority.

Summary:

Although there has been an observed decrease in the rate of infectious syphilis notifications in the Aboriginal and Torres Strait Islander population over the past five years from 234 per 100 000 in 2006 to 130 in 2010, this rate is still five times greater than in the non-Indigenous population. It is recommended that processes are established to obtain syphilis testing data to provide context to notification trends.

Decrease the proportion of HIV and hepatitis C infection caused by injecting drug use

HIV epidemics have quickly emerged among Indigenous people who inject drugs in other international settings and a greater proportion of HIV diagnoses in Australian Aboriginal and Torres Strait Islander people are reportedly due to injecting drug use, suggesting that it is important to monitor HIV transmission by this exposure route.

Proportion of Aboriginal and Torres Strait Islander people who are notified as newly diagnosed with HIV who report injecting drug use

In 2010, the population rate for HIV diagnoses among the Aboriginal and Torres Strait Islander population (4 per 100 000) was similar to that in the non-Indigenous population (4.6 per 100 000). However, surveillance data for newly diagnosed HIV infection demonstrate differences in the modes of HIV transmission between the two populations. Between 2006 and 2010, the most frequent reported mode of transmission among non-Indigenous, Australian born, was sexual contact between men (76%), followed by heterosexual contact (13%). Injecting drug use was the reported exposure among 3% of cases. Over the same time period, the most frequently reported routes of HIV transmission among Aboriginal and Torres Strait Islander people were sexual contact between men (49%), injecting drug use (19%) and heterosexual contact (19%). The percentage of newly diagnosed HIV cases among Aboriginal and Torres Strait Islander people who reported injecting drug use as the sole exposure between 2001 and 2010 is not consistent over time (Figure 40), ranging from 11% to 33%. However, this is due to the small number of diagnoses of HIV in the Aboriginal and Torres Strait Islander community (between 18 and 27 per year). Compared with the non-Indigenous population, the proportion of people with newly diagnosed HIV infection reporting injecting drug use was up to 10 times higher in the Aboriginal and Torres Strait Islander population.

There are differences between States and Territories in the proportion of Aboriginal and Torres Strait Islander people with newly diagnosed HIV who report injecting drug use as sole exposure (Table 2). However, even after combining data for the period 2001 to 2010, the numbers in each jurisdiction are small which should be taken into account when interpreting these data.
Table 2  Proportion of Aboriginal and Torres Strait Islander people with newly diagnosed HIV who report injecting drug use as the sole exposure for the period 2001 – 2010

<table>
<thead>
<tr>
<th>State</th>
<th>Percentage reporting injecting drug use as sole exposure*</th>
<th>Total number of newly diagnosed HIV cases*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>0%</td>
<td>0</td>
</tr>
<tr>
<td>NSW</td>
<td>23%</td>
<td>60</td>
</tr>
<tr>
<td>NT</td>
<td>0%</td>
<td>7</td>
</tr>
<tr>
<td>QLD</td>
<td>6%</td>
<td>54</td>
</tr>
<tr>
<td>SA</td>
<td>40%</td>
<td>15</td>
</tr>
<tr>
<td>TAS</td>
<td>0%</td>
<td>2</td>
</tr>
<tr>
<td>VIC</td>
<td>18%</td>
<td>22</td>
</tr>
<tr>
<td>WA</td>
<td>22%</td>
<td>45</td>
</tr>
<tr>
<td>Total</td>
<td>18%</td>
<td>205</td>
</tr>
</tbody>
</table>

* In the Aboriginal and Torres Strait Islander population

Figure 40  Rate of newly diagnosed HIV cases reporting injecting drug use as the sole reported exposure, 2001 – 2010, by Aboriginal and Torres Strait Islander status

Incidence of newly diagnosed hepatitis C infection in Aboriginal and Torres Strait Islander people

Information is sought for Aboriginal and Torres Strait Islander status for all hepatitis C cases notified nationally. In the Northern Territory, South Australia, Western Australia and Tasmania, Aboriginal and Torres Strait Islander status was reported for more than 50% of diagnoses of hepatitis C in 2010 where this population comprised 15%, 13% (South Australia and Western Australia) and 5%, respectively, of all hepatitis C diagnoses. Completeness of reporting for Aboriginal and Torres Strait Islander status was greater than 90% in South Australia and Western Australia.

Newly acquired hepatitis C infection is also reportable in all health jurisdictions other than Queensland but the data quality is more as discussed more fully in the section on hepatitis C indicators. Sentinel surveillance of newly acquired hepatitis C among Aboriginal and Torres Strait Islander people would more accurately ascertain the incidence of
hepatitis C in this population. This sentinel surveillance system could involve Aboriginal Community Controlled Health Services, sexual health services, public and private laboratories and potentially other sites.

Summary:

A high proportion (19%) of Aboriginal and Torres Strait Islander people diagnosed with HIV acquired infection via injecting drug use compared to non-Indigenous Australians (3%). However, there are substantial differences between jurisdictions. It is recommended that the implementation of a sentinel surveillance system for hepatitis C among Aboriginal and Torres Strait Islander people be considered.

Increase the level of testing and treatment of sexually active 15 – 30 year olds

Bacterial STIs (gonorrhoea, chlamydia and syphilis) are preventable, easy to detect and curable. Aboriginal and Torres Strait Islander young people, aged 15-30 years old, experience rates of chlamydia, gonorrhoea and infectious syphilis much greater than their non-Indigenous peers. High rates of these STIs can have important health implications if left undiagnosed and untreated.

An increase in the level of systematic testing and treatment of sexually active 15 to 30 year olds is an important measure in the decrease of bacterial STIs among young Aboriginal and Torres Strait Islander people. In the short term, successful testing and treatment strategies will increase the notifications of bacterial STIs, however, a reduction will be observed in the long term.

Proportion of Aboriginal and Torres Strait Islander young people who report having had an STI test in the previous 12 months

The proportion of Aboriginal and Torres Strait Islander young people who report having had an STI test in the previous 12 months is an indication of the level of testing in this population. No data are currently available for reporting against this indicator but self reported data on testing should be available in 2012 from a national study of young people called GOANNA (younG Aboriginal and TOreS StrAit IslaNdEr National sexual heAlth Survey). STRIVE data will also be available from 2012 from 67 remote communities. It is anticipated that studies within Aboriginal community Controlled Health Services with a format similar to ACCESS will contribute to this indicator in the future.

Rate of chlamydia tests in remote areas in NT, Qld, SA, WA in the previous 12 months

The rate of chlamydia testing in remote areas in the Northern Territory, Queensland, South Australia and Western Australia in the previous 12 months is an indication of the level of testing in the Aboriginal and Torres Strait Islander community in these areas. Data are currently not available for reporting against this indicator. Aside from STRIVE data, testing data from other remote regions in these jurisdictions should be available in 2012 upon negotiation between the Department of Health and Ageing and Medicare for data release based on VII.

Proportion of Aboriginal and Torres Strait Islander young people receiving a chlamydia and gonorrhoea test in the previous 12 months

Extension of the ACCESS project could also provide an indication of the level of chlamydia and gonorrhoea testing among young (15-29 years old) Aboriginal and Torres Strait Islander people. This indicator could be measured from enhanced sentinel surveillance sites. It is recommended that options be considered for an enhanced surveillance system which could involve Aboriginal Community Controlled Health Services, sexual health services, public and private laboratories and potentially other sites.
Summary:
Currently there are no data available for monitoring the level of systematic testing and treatment of sexually active, young Aboriginal and Torres Strait Islander people. Some data will be available in 2012. However, it is recommended that an extended and enhanced sentinel surveillance network comprised of sexual health services and Aboriginal Community Controlled Health Services be considered at a minimum.

Improve Aboriginal and Torres Strait Islander people’s knowledge of STIs and BBVs
Proportion of Aboriginal and Torres Strait Islander people giving correct answers to knowledge questions on STIs and BBVs
Improved knowledge about sexually transmitted infections (STIs) and blood borne viruses (BBVs) in the Aboriginal and Torres Strait Islander community can play an important role in encouraging safer sexual behaviours and seeking regular testing and treatment, therefore reducing the transmission of these infections.
Data on Aboriginal and Torres Strait Islander people’s knowledge of STIs and BBVs are currently not available but will be assessed using a national study of young people called GOANNA (younG Aboriginal and TOrres StrAit IslaNder National sexual heAlth Survey). These data should be available in 2012.

Summary:
Data for this indicator are not yet available.

Increase the number of Aboriginal and Torres Strait Islander peoples receiving treatment for HIV, hepatitis C and hepatitis B
Hepatitis C and hepatitis B are reported at high rates in Aboriginal and Torres Strait Islander people, disproportionate to those among non-Indigenous Australians. HIV continues to be diagnosed at a similar rate to non-Indigenous people, although the distribution of exposure differs between the two populations. There is a growing need for focused treatment programmes for each of these infections among Aboriginal and Torres Strait Islander peoples.
Calculating the extent of access to treatments for HIV, chronic hepatitis C and chronic hepatitis B among Aboriginal and Torres Strait Islander peoples is useful for various reasons. These include identification and determination of the extent of any unaddressed clinical needs of Aboriginal and Torres Strait Islander people affected by these viruses and for developing and/or improving models of access to care in order to reduce the obstacles Aboriginal and Torres Strait Islander people may face when trying to access treatment and support.

Proportion of Aboriginal and Torres Strait Islander people with HIV receiving antiretroviral treatment
To measure the proportion of Aboriginal and Torres Strait Islander people with HIV receiving antiretroviral treatment, a numerator of the number of Aboriginal and Torres Strait Islander people receiving antiretroviral treatment would be required from the Highly Specialised Drugs Program. However, this is currently unavailable. Negotiations are to be made by the Department of Health and Ageing with Medicare for the routine release of Highly Specialised Drugs Program data, cross tabulated by Voluntary Indigenous Identifier data. The denominator for this indicator would be the number of Aboriginal and Torres Strait Islander people on the National HIV Registry.
Proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis C who are dispensed drugs for hepatitis C infection through the Highly Specialised Drugs Program in the previous 12 months

To measure the proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis C receiving antiviral treatment for hepatitis C, a numerator of the number of Aboriginal and Torres Strait Islander people receiving appropriate treatment for hepatitis C would be required from the Highly Specialised Drugs Program. However, this is currently unavailable. Similar to the previous indicator, negotiations are to be made by the Department of Health and Ageing with Medicare for the routine release of Highly Specialised Drugs Program data, cross tabulated by Voluntary Indigenous Identifier data. The denominator for this indicator would be a model-based estimate number of Aboriginal and Torres Strait Islander people with hepatitis C.

Proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis B who are dispensed drugs for hepatitis B infection through the Highly Specialised Drugs Program in the previous 12 months

To measure the proportion of Aboriginal and Torres Strait Islander people with chronic hepatitis B receiving antiviral treatment for hepatitis B, a numerator of the number of Aboriginal and Torres Strait Islander people receiving appropriate treatment for hepatitis B would be required from the Highly Specialised Drugs Program. However, this is currently unavailable. Similar to the previous two indicators, negotiations are to be made by the Department of Health and Ageing with Medicare for the routine release of Highly Specialised Drugs Program data, cross tabulated by Voluntary Indigenous Identifier data. The denominator for this indicator would be a model based estimate number of Aboriginal and Torres Strait Islander people with hepatitis B.

Summary:

Data for these three indicators of treatment coverage for Aboriginal and Torres Strait Islander people with HIV, chronic hepatitis C and chronic hepatitis B are currently unavailable. Negotiations with Medicare to release data from the Highly Specialised Drugs Program, cross tabulated by Voluntary Indigenous Identifier data must be made in order to report against these measures.

Implement a national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers

A strong and competent health care workforce is required to effectively address STIs and BBVs in the Aboriginal and Torres Strait Islander population. There is a need to increase the number of Aboriginal and Torres Strait Islander sexual health workers and to provide them with ongoing support and professional development opportunities. In order to facilitate this, the national registration and accreditation scheme for sexual health professionals, implemented by the Coalition of Australian Governments, should be extended to Aboriginal and Torres Strait Islander sexual health workers.

Number of Aboriginal and Torres Strait Islander people registered under the National Registration Program

To measure the progress of this national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers, the number of people registered under the National Registration program will be the key indicator. This information will not be available until the National Registration Program is implemented.

Summary:

A national accreditation scheme for Aboriginal and Torres Strait Islander sexual health workers will facilitate their support and ongoing professional development. Until the scheme is implemented, this indicator will not be reported against.
References


# Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCESS</td>
<td>Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance</td>
</tr>
<tr>
<td>AHOD</td>
<td>Australian HIV Observational Database</td>
</tr>
<tr>
<td>AHPC</td>
<td>Australian Health Protection Committee</td>
</tr>
<tr>
<td>ANSPS</td>
<td>Australian Needle and Syringe Program Survey</td>
</tr>
<tr>
<td>APHDPC</td>
<td>Australian Population Health Development Principal Committee</td>
</tr>
<tr>
<td>ART</td>
<td>Anti retroviral therapy</td>
</tr>
<tr>
<td>BBV</td>
<td>Blood Borne Virus</td>
</tr>
<tr>
<td>BBVSS</td>
<td>Blood Borne Virus and Sexually Transmissible Infections Sub-Committee of the APHDPC</td>
</tr>
<tr>
<td>BED-CEIA</td>
<td>BED capture enzyme immunoassay</td>
</tr>
<tr>
<td>CDNA</td>
<td>Communicable Diseases Network Australia</td>
</tr>
<tr>
<td>DBS</td>
<td>Dried blood spots</td>
</tr>
<tr>
<td>GCPS</td>
<td>Gay Community Periodic Surveys</td>
</tr>
<tr>
<td>GP</td>
<td>General Practice</td>
</tr>
<tr>
<td>HCC</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>HITS-c</td>
<td>NSW Hepatitis C Incidence and Transmission – community</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HSD</td>
<td>Highly Specialised Drugs</td>
</tr>
<tr>
<td>NCHSR</td>
<td>NCHSR</td>
</tr>
<tr>
<td>NSP</td>
<td>Needle and Syringe Programs</td>
</tr>
<tr>
<td>PWID</td>
<td>People who inject drugs</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic Acid</td>
</tr>
<tr>
<td>STRIVE</td>
<td>STI in Remote communities: Improved &amp; Enhanced primary health care</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually transmissible infection</td>
</tr>
</tbody>
</table>
Acknowledgements

Groups and committees involved in the development of the Surveillance and Monitoring Plan and this associated Report, as well as the individuals and organisations who provided data for inclusion in this report are listed below.

National Blood Borne Virus and Sexually Transmissible Infection Surveillance Sub-Committee of CDNA

- Dr Christine Selvey (chair)
- Dr Benjamin Cowie
- Prof John de Wit
- Ms Ellen Donnan
- Ms Paula Spokes
- Ms Carolien Giele
- A/ Prof Margaret Hellard
- Ms Rebecca Hundy
- Prof John Kaldor
- Ms Ann McDonald
- Ms Melanie Middleton
- Mr Darryl O’Donnell
- Ms Kate Pennington
- Mr Jiunn-yih Su
- Dr Mark Veitch
- Dr Russell Waddell
- Mr James Ward
- Ms Jo Watson
- A/ Prof David Wilson

National BBV and STI Surveillance and Monitoring Plan Steering Committee Executive

- Dr Christine Selvey (chair)
- Ms Lisa Bastian
- Ms Victoria Bryant
- Ms Sally Goodspeed
- Prof John Kaldor
- Dr Jeremy McAnulty
- Mr Darryl O’Donnell
- Ms Megan Parrish
- Ms Erin Passmore
- A/ Prof David Wilson

National BBV and STI Surveillance and Monitoring Plan Steering Committee

- Dr Christine Selvey (chair)
- Mr Brent Allan
- Ms Lisa Bastian
- Prof Frank Bowden
- Dr Graham Brown
- Prof Greg Dore
- Ms Amalie Dyda
- Dr Patricia Fagan
- Dr Rebecca Guy
- Dr Jane Hocking
- Prof Christopher K Fairley
- A/ Prof Margaret Hellard
- Prof John Kaldor
- Prof Lisa Maher
- Dr Jeremy McAnulty
- Ms Anne Marie Mioche
- Mr Darryl O’Donnell
- Ms Megan Parrish
- Ms Erin Passmore
- Prof Marian Pitts
- A/ Prof Garrett Prestage
- Ms Kate Pennington
- Dr Jiunn-yih Su
- Dr Mark Veitch
- Dr Russell Waddell
- Mr James Ward
- Ms Jo Watson
- A/ Prof David Wilson
- Dr Teresa Wozniak

National BBV and STI Surveillance and Monitoring Plan Working Groups

Aboriginal and Torres Strait Islander Working Group

- Mr James Ward (chair)
- Dr Patricia Fagan (co-chair)
- Ms Amalie Dyda
- Dr Rae-Lin Huang
- Dr Nathan Ryder
- Dr Jiunn-yih Su
Hepatitis B Working Group

- Prof John Kaldor (chair)
- Professor Frank Bowden (co-chair)
- Dr Benjamin Cowie
- Dr Mitchell Smith
- Ms Helen Tyrrell
- Dr Mark Veitch

Hepatitis C Working Group

- Prof Lisa Maher (chair)
- Ms Lisa Bastian (co-chair)
- Prof Robert Batey
- Prof Greg Dore
- A/Prof Margaret Hellard
- Mr Stuart Loveday
- Ms Annie Madden
- Dr Mark Stoove

HIV Working Group

- A/Prof David Wilson (chair)
- Dr Graham Brown (co-chair)
- Mr Brent Allan
- Ms Ann McDonald
- A/ Prof Garrett Prestage
- Ms Jo Watson

STI Working Group

- Prof Christopher K Fairley (chair)
- Dr Russell Waddell (co-chair)
- Dr Christopher Bourne
- Dr Rebecca Guy
- Dr Jane Hocking
- Mr Darryl O’Donnell
- Prof Marian Pitts

National organisations

- Association for Prevention and Harm Reduction Programs, VIC
- Australasian Society for HIV Medicine, Sydney, NSW
- Australian Federation of AIDS Organisations, Sydney, NSW
- Australian Government Department of Health and Ageing, Canberra, ACT
- Australian Injecting and Illicit Drug Users’ League
- Australian Institute of Health and Welfare, Canberra, ACT
- Australian Research Centre in Sex, Health & Society, Melbourne, VIC
- Communicable Diseases Network Australia, Canberra, ACT
- Hepatitis Australia, Canberra, ACT
- National Aboriginal Community Controlled Health Organisation, ACT
- National Association of People Living with HIV/AIDS, Sydney, NSW
- National Centre in HIV Social Research, The University of New South Wales, NSW
- National Drug and Alcohol Research Centre, The University of New South Wales, Sydney, NSW

State/Territory health departments

- Communicable Disease Control Program, ACT Department of Health and Community Care, Canberra, ACT
- Centre for Health Protection, NSW Health Department, North Sydney, NSW
- AIDS/STD Program, Disease Control, Department of Health, Darwin, NT
- Queensland Health, Brisbane, QLD
- Sexually Transmitted Diseases Services, Internal Medicine Service, Royal Adelaide Hospital, SA
- Department of Community and Health Services, Hobart, TAS
- Communicable Disease Prevention and Control Unit, Department of Health, Victoria; The Macfarlane Burnet Institute for Medical Research and Public Health Limited, Prahran, VIC
- Communicable Diseases Control Branch, Department of Health, Perth, WA
Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance (ACCESS)

- Australian Government Department of Health and Ageing, Canberra, ACT
- National Aboriginal Community Controlled Health Organisation, ACT
- The Kirby Institute, The University of New South Wales, Sydney
- Perinatal and Reproductive Epidemiology Research Unit, incorporating the National Perinatal Statistics Unit, The University of New South Wales, Sydney, NSW
- Centre for Population Health, Burnet Institute, Melbourne; National Serology Reference Laboratory, Australia, Fitzroy, VIC

ACCESS contributing organisations

- Coffs Harbour Sexual Health Service, Coffs Harbour; Grafton Sexual Health Clinic, Grafton; Greater Southern Area Health Service; Holden Street Clinic, Gosford; Hunter New England Sexual Health Service; Illawarra Sexual Health, Wollongong; Kirketon Road Centre, Darlinghurst; Lismore/Tweed Heads Sexual Health & AIDS Services, Lismore; Northern Sydney Sexual Health Service, St Leonards; Orange Sexual Health Service, Orange; Royal Prince Alfred Hospital Sexual Health Clinic, Camperdown; Short Street Sexual Health Clinic; St George Hospital; Sydney Sexual Health Centre, Sydney; Sydney West Area Health Service – Clinical Sexual Health Services, NSW
- NT Sexual Health and BBV Unit, NT
- Cairns Sexual Health Services, Cairns Base Hospital, Cairns; Gold Coast Sexual Health Clinic, Miami; Princess Alexandra Sexual Health, Princess Alexandra Hospital, Woolloongabba; Townsville Sexual Health Service, Townsville, QLD
- Hobart, Devonport and Launceston Sexual Health Service, TAS
- Melbourne Sexual Health Centre, Carlton, VIC
- Fremantle Hospital, Fremantle, WA

Australian HIV Observational Database

- Tamworth Sexual Health Service, Tamworth Blue Mountains Sexual Health Clinic, Katoomba; Holdsworth House Medical Practice, Darlinghurst; Illawarra Sexual Health, Wollongong; Royal Prince Alfred Hospital Sexual Health Clinic, Camperdown; Macquarie Sexual Health Centre, Dubbo; Nepean Sexual Health and HIV Clinic, Penrith; Holden Street Clinic, Gosford; Lismore Sexual Health & AIDS Services, Lismore; St Vincent’s Hospital, Darlinghurst, Sydney Sexual Health Centre, Sydney, Dr Ellis General Medical Practice, Coffs Harbour; Taylor Square Private Clinic, Darlinghurst; East Sydney Doctors, Surry Hills, NSW
- Communicable Disease Centre, Royal Darwin Hospital, Darwin, NT
- AIDS Medical Unit, North Quay; Clinic 87, Sunshine Coast & Cooloola HIV Sexual Health Service, Nambour; Gladstone Road Medical Centre, Highgate Hill; Gold Coast Sexual Health Clinic, Miami; Cairns Sexual Health Services, Cairns Base Hospital, Cairns, QLD
- The Care and Prevention Program, Adelaide University, Adelaide, SA
- The Alfred Hospital, Prahran; Melbourne Sexual Health Centre, Carlton; Monash Medical Centre, Clayton; Prahran Market Clinic, South Yarra; The Centre Clinic, St Kilda; The Carlton Clinic, Carlton; Northside Clinic, Fitzroy North, VIC
- Department of Clinical Immunology, Royal Perth Hospital, Perth, WA

Collaboration of Australian Needle and Syringe Programs

- Directions ACT, Canberra;
- Albury Community Health Centre, Albury; Central Coast NSP Services, Gosford and Long Jetty; First Step Program, Port Kembla and Nowra; Health ConneXions Harm Reduction Program, Liverpool; Hunter Harm Reduction Services and Hunter ACON, Newcastle; Kirketon Road Centre and K2, Kings Cross; NSW Users and AIDS Association (NUAA), Surry Hills; Northern Coast Area Health Service, Ballina, Byron Bay, Coffs Harbour, Grafton, Lismore, Murwillumbah, Nimbin, and Tweed Heads; Resource and Education Program for IDUs, Redfern; Central Access Service, Kogarah and Sutherland; Sydney West Area Health Service HIV/Hepatitis C Prevention Service, Blacktown, Mt Druitt, Nepean and Parramatta;
• Northern Territory AIDS and Hepatitis C Council, Alice Springs, Darwin and Palmerston;
• Biala Community Alcohol and Drug Services, Brisbane; Cairns ATODS NSP, Cairns; Queensland Injectors Health Network (QuIHN), Brisbane, Gold Coast and Sunshine Coast; Kobi House, Toowoomba; West Moreton Sexual Health Service, Ipswich; Townsville ATODS NSP;
• Drug and Alcohol Services South Australia, Adelaide; Hindmarsh Centre, Hindmarsh; Nunkuwarrin Yunti Community Health Centre, Adelaide; South Australia Voice for Intravenous Education (SAVIVE): AIDS Council South Australia, Norwood; Parks Community Health Service, Adelaide; Port Adelaide Community Health Service, Port Adelaide; Noarlunga Community Health Service, Adelaide; Northern Metropolitan Community Health Service NSP and Shopfront, Salisbury;
• Clarence Community Health Centre, Clarence; Salvation Army Launceston, Launceston; Tasmanian Council on AIDs, Hepatitis & Related Diseases (TasCAHRD), Hobart and Glenorchy;
• Barwon Health Drug and Alcohol Services, Geelong; Darebin Community Health Centre, Northcote; Health Information Exchange, St Kilda; Inner Space, Collingwood; North Richmond NSP, North Richmond; Southern Hepatitis/HIV/AIDS Resource and Prevention Service (SHARPS), Frankston;
• WA AIDS Council Mobile Exchange, Perth; Western Australia Substance Users Association (WASUA), Perth and South Coast;
• Centre for Applied Medical Research (AMR) and NSW State Reference Laboratory for HIV, St Vincent’s Hospital, Sydney, NSW

Surveillance and Monitoring Report Internal Working Group of the Kirby Institute

• A/ Prof David Wilson (chair)
• Prof Tony Butler
• Prof David Cooper
• Prof Basil Donovan
• Prof Gregory Dore
• Prof Sean Emery
• Prof Andrew Grulich
• Dr Rebecca Guy
• Prof John Kaldor
• Prof Lisa Maher
• Ms Ann McDonald
• Dr Joanne Micallef
• Ms Melanie Middleton
• Dr Kathy Petoumenos
• A/Prof Garrett Prestage
• Dr Libby Topp
• Mr James Ward